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ABSTRACT OF THESIS 
 
 
VOCAL FUNCTION EXERCISES FOR NORMAL VOICE: 
THE EFFECTS OF VARYING DOSAGE 
 
 
The primary purpose of this investigation was to explore the effects of variable 
doses of home practice Vocal Function Exercises (VFEs) on attainment of pre-
established maximum phonation time (MPT) goals in individuals between the ages of 18 
and 25 with normal voice.  A secondary purpose was to monitor for potentially toxic 
effects of high doses of VFEs.  Three experimental groups completed a six-week VFE 
protocol and practiced twice daily.  The low dose group performed each exercise once, 
the traditional group twice, and the high dose group four times.  Results indicated 
significant change in VFE MPT for all three groups and higher goal attainment in the 
high dose group.  Low doses appear insufficient to produce substantial change in voice 
production.  Acoustic MPT improved most in the traditional dosage group, which also 
exhibited best maintenance and best overall outcomes.  No toxic effects in vocal fold 
condition or phonation were observed or measured secondary to high VFE exposure. 
 
KEYWORDS: Vocal Function Exercises, dose, intensity, maximum phonation time, 
compliancy, voice disorders 
 
 
 
 
 
    Maria Holland Bane   
 
                     4/14/2016               
 
 
 	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
VOCAL FUNCTION EXERCISES FOR NORMAL VOICE: 
THE EFFECTS OF VARYING DOSAGE 
 
 
By 
 
Maria Holland Bane 
 
 
 
 
 
 
 
 
 Joseph Stemple, Ph.D., CCC-SLP, ASHAF 
Director of Thesis 
 
  Anne Olson, Ph.D., CCC/A    
Director of Graduate Studies 
 
  4/14/2016                  
 
 
 
 
 	 iii	
ACKNOWLEDGEMENTS 
 
I would like to extend my sincere appreciation to the many people who made this 
thesis possible.  This endeavor was only completed with the support, encouragement, and 
bright ideas of many individuals.  First and foremost I would like to thank my mentor and 
committee chair, Joseph Stemple, Ph.D., CCC-SLP, ASHA-F, who provided me with 
countless hours of teaching and support in study design, training, monitoring, data 
collection, and proof reading.  Most importantly, I would like to extend my gratitude to 
Dr. Stemple for the most important contribution to this project: instilling in me the 
courage to embark on a Master’s thesis and the belief that I could be successful in doing 
so.  His enthusiasm for the pursuit of knowledge has been truly infectious and has 
changed the course of my academic and professional career.  For this, I am forever 
grateful. 
Thank you to committee member Richard Andreatta, Ph.D., for his indispensable 
contributions to study design and for the time he spent preparing me to share and present 
this project.  I also extend thanks to committee member Gilson Capilouto, Ph.D., CCC-
SLP for her suggestions regarding study design, her keen proof-reading abilities, and her 
work through the undergraduate research program that allowed me access to research 
assistants. 
Thank you to committee member Vrushali Angadi, M.S., CCC-SLP, ABD, who 
provided essential input for study design, IRB approval, and statistical analysis.  Vrushali 
was integral to training, supervision, and data collection throughout the study.  Thank you 
also to JoAnna Sloggy, M.A., CCC-SLP and Dan Croake, M.M., M.S., CCC-SLP, ABD, 
who provided countless hours of support with training, supervision, and data collection. 
 	 iv	
I would also like to thank the University of Kentucky Academic, Enterprise, and 
Voice and Swallow Clinics, including Debra Suiter, Ph.D., CCC-SLP, BRS-S, Donna 
Morris, M.A., CCC-SLP, Kim West, Ellen Hagerman, M.S., CCC-SLP, Meg Shake, 
M.S., CCC-SLP, Melissa Liechty, M.S.P., CCC-SLP, and Christina Gonzales-Sanders, 
M.S., CCC-SLP, who provided logistical support with scheduling, research facilities, and 
instrumental equipment, as well as professional and academic support.   
Thank you to the six research assistants and 28 research participants who, through 
their dedication and passion for this field, made this project possible.   
Finally, thank you to my incredible family, outstanding colleagues, and 
supportive friends who helped me treasure this experience.   
This thesis has certainly been a formative experience for my future academic, 
clinical, and investigative pursuits.  I look forward to continued guidance under excellent 
mentors.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	 v	
TABLE OF CONTENTS 
 
Acknowledgments .......................................................................................................... iii 
 
List of Tables ................................................................................................................. vii 
 
Chapter One: Introduction 
The difficulty of determining dose for behavioral interventions ....................... 2 
Statement of the problem ................................................................................... 5 
Purpose of the study ........................................................................................... 7 
Chapter summary ............................................................................................... 8 
 
Chapter Two: Literature Review 
VFEs for normal voice ....................................................................................... 9 
VFEs for disordered voice ................................................................................. 9 
VFEs as a standard of care ................................................................................. 14 
VFE dose ............................................................................................................ 15 
Other voice interventions and dose .................................................................... 18 
Principles of sensory motor learning and dose .................................................. 23 
Research hypotheses .......................................................................................... 25 
Chapter summary ............................................................................................... 25 
 
Chapter Three: Methodology 
Participants ......................................................................................................... 26 
Exercise procedure ............................................................................................. 26 
Training .................................................................................................. 27 
Compliance and home practice .............................................................. 27 
Weekly check-ins ................................................................................... 28 
Outcome measures/ assessment parameters ....................................................... 28 
Chapter summary ............................................................................................... 29 
 
Chapter Four: Results 
Demographics .................................................................................................... 30 
Groups .................................................................................................... 31 
Withdrawal questionnaires ..................................................................... 32 
Baseline measures .............................................................................................. 33 
Outcome measures ............................................................................................. 34 
Primary outcome measures .................................................................... 34 
Toxicity .................................................................................................. 38 
Secondary outcome measures ................................................................ 39 
Summary of outcome measures ............................................................. 41 
Compliance ........................................................................................................ 43 
Chapter summary ............................................................................................... 44 
 
 
 
 	 vi	
Chapter Five: Discussion 
Review of purpose ............................................................................................. 45 
Review of methodology ..................................................................................... 45 
Discussion of results .......................................................................................... 46 
Group homogeneity ............................................................................... 46 
Withdrawal rates .................................................................................... 46 
Goal attainment ...................................................................................... 47 
Primary outcome measures .................................................................... 48 
Toxicity .................................................................................................. 50 
Secondary outcome measures ................................................................ 51 
Summary of outcome measures ............................................................. 52 
Compliance ............................................................................................ 53 
Limitations and delimitations ............................................................................ 54 
Implications for future research ......................................................................... 56 
Significance of the study .................................................................................... 57 
Contribution to the literature on dosage ................................................. 58 
Dosage as integral to principles of sensory motor learning ................... 59 
Specificity .................................................................................. 60 
Intensity ...................................................................................... 60 
Repetition ................................................................................... 61 
Clinical implications .............................................................................. 61 
Conclusions ........................................................................................................ 62 
Chapter summary ............................................................................................... 64 
 
Appendices 
Appendix A: Recruitment Flyer ......................................................................... 65 
Appendix B: Consent Form ............................................................................... 66 
Appendix C: Inclusion/ Exclusion Criteria Checklist ........................................ 73 
Appendix D: Study Checklist ............................................................................ 74 
Appendix E: Consensus Auditory-Perceptual Evaluation of Voice .................. 75 
Appendix F: Voice Related Quality of Life ....................................................... 76 
Appendix G: Vocal Function Exercise Program ............................................... 77 
Appendix H: Withdrawal Questionnaire ........................................................... 78 
Appendix I: Average Weekly Phonation Times (s) ........................................... 79 
 
References ...................................................................................................................... 80 
 
Vita ................................................................................................................................. 85 
 
 
 
 
 	 vii	
LIST OF TABLES 
 
Table 4.1, Demographics ............................................................................................... 31 
Table 4.2, Dosage Assignments ..................................................................................... 31 
Table 4.3, Withdrawal Questionnaire Results ............................................................... 32    
Table 4.4, One-Way ANOVAs for Baseline Measures ................................................. 34 
Table 4.5, Primary Outcome Measures: VFE MPT & Acoustic MPT .......................... 37 
Table 4.6, Paired Sample T-Tests for Primary Outcome Measures .............................. 38 
Table 4.7, Paired Sample T-Tests for Secondary Outcome Measures .......................... 40 
Table 4.8, Number of Significant Changes in Outcome Measures ................................ 43 
Table 4.9, Home Exercise Compliance by Dosage Group ............................................ 44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 	 1	
Chapter One: Introduction 
While many Phase 1 trials demonstrate positive treatment effects for various 
interventions in speech-language pathology, most treatments currently employed have 
little to no information from Phase 2 trials providing guidance on dose-response 
relationships (Roy, 2012).  This issue is especially salient in the area of voice therapy, 
where dosing can mean the difference between no effect, the ideal effect, and toxic or 
adverse effects.  In fact, Titze (1994) suggested that vocal fold injury can occur as a result 
of exceeding a certain “vibration dose,” and many clinicians believe that vibration 
overdose is toxic.  Due to this belief, a common approach is to limit acceleration and 
shearing forces on the vocal fold mucosa.  Traditionally, vocal load has been reduced 
using intervention approaches such as vocal hygiene, which seeks to eliminate 
phonotraumatic behaviors and educate clients about vocal health.  However, vocal load 
can also be reduced by exercises that train the vocal mechanism in ways that increase the 
efficiency (and decrease the phonotrauma) of vibration (Titze, 2006).  One such strategy 
is Vocal Function Exercises (VFEs), a direct training approach that seeks to strengthen 
and rebalance the laryngeal musculature and enhance the relationship among the three 
subsystems of voice: respiration, phonation, and resonance (Stemple, Lee, D’Amico, & 
Pickup, 1994). 
While a variety of studies have demonstrated VFEs to be effective in enhancing 
both normal and pathological voices, little is known about the ideal dose, or the dose that 
yields the greatest benefit without causing damage (Roy, 2012).  Because practicing these 
exercises increases vocal load by increasing vibration, and because VFEs require 
vocalizing at the extreme ends of the pitch range, it is conceivable that excessive amounts 
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of practice could result in damage to the vocal mechanism.  Although these exercises 
must be carefully monitored in order to prevent potential harm, the VFE regimen also 
requires a substantial amount of home practice, meaning that the exercises are frequently 
performed independently and without clinical supervision (Roy, 2012).  While according 
to Stemple et al. (1994) the standard protocol for home practice involves performing a set 
of four exercises two times each both morning and evening, clinicians actually know very 
little about the ideal dose for VFEs (Roy, 2012).  Without more information regarding the 
dose-response relationship for VFEs, it is possible that the over-zealous patient, or even 
clinician, could misguidedly assume that more is better.  
The Difficulty of Determining Dose for Behavioral Interventions  
Despite the potentially harmful effects of vibration overdose, the concept of 
toxicity is rarely considered in voice therapy (Roy, 2012).  There exist a variety of 
obstacles to determining the ideal dose in interventions like VFEs.  One issue is difficulty 
identifying the active ingredient within the intervention.  Most behavioral interventions 
consist of a variety of potentially active ingredients that include both clinician and client 
acts and ultimately function to affect change in client behavior (Baker, 2012).  Although 
it is postulated that the benefits of VFEs stem from strengthening, rebalancing, and 
coordinating the laryngeal musculature, this remains unclear.  The controversy lies in the 
fact that the principles of exercise physiology and motor learning are primarily borrowed 
from knowledge on limb musculature, and only a superficial link exists between the 
musculature of the limbs and that of the larynx (Roy, 2012).  If principles of motor 
learning do indeed apply to the laryngeal musculature, one must also consider the concept 
that when intervention involves learning a motor skill, it is thought to be accomplished 
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both online (through practice) as well as offline (through memory consolidation) (Yan, 
Abernethy, & Li, 2010).  It is difficult to identify the precise neural substrates that 
underlie offline learning and to quantify those in order to account for them while 
determining optimal dose.  Complicating this matter is that it may take several days for 
underlying neural changes to catch up to behavioral changes being made by the 
individual (Kleim & Jones, 2008).   
A second obstacle to identifying the ideal dose is that interventions in voice 
therapy often operate non-linearly.  For example, incremental adjustments may result in 
substantial changes (either positive or negative) in overall voice production and quality 
(Roy, 2012).  Without knowing the threshold between the ideal dose and the toxic dose, it 
is difficult to pinpoint either one.   
A third issue in determining dosage is that of individual variability.  Some 
individuals will be intrinsically pre-disposed to vibration overdose while others will be 
hypo-responsive to a given dose or intervention (Roy, 2012).  In other words, a dose that 
provides no measureable effect for one individual may prove to be toxic for another.  
While these variables exist within the client, there are also external variables such as 
motivation, financial resources, and family support that may contribute to deciding which 
dose is even feasible (Baker, 2012).   
Fourth, even if an ideal dose were established in the research setting, there are 
challenges to implementation in the clinical setting.  VFEs constitute a fairly prescriptive 
regimen and, in the clinical setting, are often used in combination with other 
interventions and modified for the individual client.  It is unknown whether combinations 
of treatments result in additive effects that yield increased benefits or whether they reach 
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the point of toxicity.  There is also the potential that combined treatments operating from 
opposing conceptual standpoints will result in no measureable effect (Roy, 2012).     
Fifth, Baker (2012) raises yet another complication in quantifying dose: the idea 
that dosage can be influenced by target selection.  For example, an intervention for 
Parkinson’s Disease, the Lee Silverman Voice Treatment (LSVT®), is typically done on 
an intense schedule of four times a week for four weeks with additional daily home 
practice.  Fox, Ramig, Ciucci, Sapir, McFarland, and Farley (2006) argue that selecting 
the single target of increased SPL (loudness) encourages cross-system improvements and 
leads to significant change in areas such as facial expression, articulation, swallowing, 
respiratory support, and limb movements.  Thus, target selection may ultimately 
influence the required dose and the overall length of intervention (Baker, 2012).   
Finally, these issues are further compounded by disagreement on what constitutes 
“intense” treatment and how one goes about quantifying dosage.  High dose and intense 
treatment are not mutually inclusive, since a given dose may be delivered with or without 
intensity, and an intense treatment may ultimately be delivered in a lower dose, or even 
require a lower dose because of its intensity.  In a lead article to a scientific forum on 
optimal intensity, Baker (2012) illustrates the many facets of the concept of dosage and 
proposes a model for its measurement.  She argues that in the field of speech-language 
pathology, not only the quantity but also the quality of intervention must be considered.  
While dose can be defined in various ways that consider number and duration of sessions, 
overall length of intervention, density of teaching episodes, and number of client 
responses, the common denominator is the concept of “repeated, spaced episodes of 
intervention over a period of time” (Baker, 2012, p. 402).  To account for the many 
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variables that contribute to a given dose, Baker borrows from the work of Warren, Fey, 
and Yoder (2007) and discusses the concept of cumulative intervention intensity, or the 
product of dose, dose frequency, and total intervention duration.  Dose denotes the 
quantity of teaching episodes occurring per session.  Dose frequency refers to the number 
of intervention sessions per unit of time, and total intervention duration refers to the total 
period of time over which an intervention takes place (Warren et al., 2007).  Taken 
together, these aspects of intervention help account for both quantity and quality of a 
given treatment.  Baker then proposed her own modifications to this model for 
quantifying intervention.  The model accounts not only for the dose (therapy session) and 
teaching episodes within the session, but also for the active ingredients, which are 
categorized as either clinician inputs (expansions, models, recasts, questions) or client 
acts (production practice of a skill).  She further recommended that at-home work be 
accounted for when calculating dose.  Cumulative intervention intensity, then, would 
“comprise the total from each ingredient provided using SLP time, and the total from 
each ingredient involving non-SLP time” (Baker, 2012, p. 405).  Thus, dose is the 
number of correct responses in a practice session in therapy or at home.  In this way, both 
clinician-guided and independent learning are accounted for.  It is with Baker’s 
framework in mind that this discussion on dosage for VFEs begins. 
Statement of the Problem 
Ultimately, inaccurate doses can be more harmful than they are beneficial.  As 
Baker (2012) explains, this is evident in pharmacology, where not only does the dose 
make the poison, but under-dosing can be equally perilous.  For example, an under-dose 
of penicillin was thought to be worse than an over-dose because it resulted in the survival 
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of penicillin-resistant microbes (Fleming, 1945).  Nonetheless, overdose has been more 
closely affiliated with detrimental effects, as in the case of excessive vitamin B6 
supplementation resulting in sensory neuropathy (Schaumburg, Kaplan, Windebank, 
Vick, Rasmus, Pleasure, et al., 1983).  While pharmacological models of toxicity may not 
be applicable to all fields of speech-language pathology, the model is appropriate for 
some voice interventions, especially given the aforementioned potential for toxic levels 
of vocal exercises (Roy, 2012).   
Beyond the potential danger of toxicity, the amount of necessary intervention is a 
salient aspect of effective treatment for the voice pathologist.  While intense treatment 
may elicit better outcomes, more is not always better because intensity and outcomes do 
not necessarily enjoy a linear relationship (Baker, 2012; Roy, 2012).  Too little of an 
intervention may lead to poorer outcomes, frustrate the client, and fail to resolve vocal 
issues which may ultimately result in social withdrawal, occupational difficulty, and 
reduced quality of life.  Under-dosing may also make treatment as (in)effective as no 
intervention at all.  Conversely, too high of a dose may produce diminishing returns, have 
no additional effect, or, as previously discussed, become harmful (Baker, 2012; Roy, 
2012).  Over-dosing may also prompt heavier caseloads and ultimately poorer quality of 
care by increasing the burden on professionals.  In both cases, inaccurate doses do not 
result in optimal outcomes and are therefore wasteful.  The cost is multi-faceted in terms 
of time, money, and resources.  It is vital that treatment be not only effective but efficient 
as well (Baker, 2012).  Additionally, efficiency of treatment may be affected by factors 
outside the clinician’s control, such as compliance and attendance. 
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Thus, information on dosage increases the efficacy and efficiency of voice 
interventions such as VFEs, avoids causing potential harm, improves cost-efficiency and 
productivity, and has important implications for clinicians, clients, and third party payers.  
Currently, the dearth of literature on appropriate dosing squanders resources and leaves 
clinicians, especially new clinicians lacking experience, to guess at appropriate 
intervention intensity.  The problem is that the ideal dose of VFEs is simply unknown 
because it has not been thoroughly investigated.     
Purpose of the Study 
This study addressed dosage of a specific physiologic voice therapy delivered by 
voice pathologists, Vocal Function Exercises, as applied to a population with normal 
voice.  Individuals with normal voice were selected because the absence of phase II dose-
response studies made it prudent to begin investigation in the normal voice.  Because 
vocal wellness exists on a continuum that includes the disordered, normal, and trained 
voice, individuals are always capable of improving their voice production.  The 
intervention of focus here, VFEs, while aimed primarily at improving the disordered 
voice, may be equally effective for enhancing normal voice (Stemple et al., 1994).  The 
approach is holistic in that it attends to all three subsystems of voice, which are 
interconnected and interdependent.  Thus, any disturbance in one of the subsystems 
affects the other two, resulting in some form of compensation and physiologic imbalance.  
This imbalance may come to be perceived as a voice disorder, or it may simply result in 
less efficient functioning of the entire system (Stemple, 2005).  The ultimate goal of the 
exercise regimen is to strengthen, rebalance, and coordinate the laryngeal musculature 
through a series of four exercises: a warm up exercise, stretching exercise, contracting 
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exercise, and low impact adductory power exercise (Stemple et al., 1994).  In essence, 
these vocal exercises improve the efficiency of vibration and voice production, but the 
ideal dose for doing so remains unknown.    
Three experimental groups with low, traditional, and high exposure to VFEs were 
monitored to facilitate comparison in time to goal attainment and voice quality 
improvement along perceptual, acoustic, and aerodynamic parameters.  Potential toxicity 
was monitored using visual observation (stroboscopic examination) and participant self-
report.  The primary purpose of the study was to investigate whether increased intensity 
of at-home practice results in faster goal attainment in terms of maximum phonation time 
(MPT).  This study also sought to observe diminishing returns and monitor for adverse 
effects of high VFE dosage, and to compare maintenance one moth post-treatment across 
different dosage intensity groups.   
Chapter Summary 
Chapter one was meant as an introduction to the concept of dose as it applies to 
behavioral interventions, specifically in the area of voice.  Chapter two will serve to 
review the relevant literature.   
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Chapter Two: Literature Review 
Previous research has demonstrated VFEs to be effective in improving both the 
normal and the pathological voice.  There are 24 studies that explore using VFEs in a 
variety of populations.  In the disordered voice, VFEs may improve hyperfunctional as 
well as hypofunctional disorders, and may be used in combination with other treatment 
approaches to maximize outcomes.  Most recently, VFEs have been used as an 
established therapeutic technique for comparison to newer interventions.   
VFEs for Normal Voice 
  Regarding VFE application to normal voice, Stemple et al. (1994) performed a 
double-blind, placebo-controlled study which demonstrated maximized use of phonation 
flow volume, decreased airflow rate, increased MPT, increased frequency range, and 
improved symmetry of vibration in adult women.  VFEs have also been shown to 
significantly improve airflow volume, airflow rate, MPT, and dynamic range in opera 
students with normal voice as compared to a control group (Sabol, Lee, & Stemple 1995).  
Additionally, VFEs resulted in improved vocal efficiency in children with normal voice 
who sing (Sayles, 2003).  Finally, Guzman, Angulo, Muñoz, and Mayerhoff (2013) found 
that VFEs positively affect voice quality when used in conjunction with vocal warms ups 
for pop singers with perceptually normal voices when compared to a control group.  In 
conclusion, there is evidence to suggest that VFEs improve normal voice in non-singers, 
opera singers, children, and pop singers.   
VFEs for Disordered Voice 
VFEs are also efficacious in improving disordered voice, and evidence 
demonstrates improvements in hyperfunctional as well as hypofunctional disorders.  A 
 	 10	
study by Roy, Gray, Simon, Dove, Corbin-Lewis, and Stemple (2001) found improved 
Voice Handicap Index (VHI) scores, self-reported overall voice improvement, greater 
vocal clarity, and greater ease of speaking in elementary and secondary teachers with 
self-reported voice problems who followed a VFE regimen when compared to a control 
group and a vocal hygiene (VH) group.  Similarly, Gillivan-Murphy, Drinnan, O’Dwyer, 
Ridha, and Carding (2006) found significant improvements on a voice symptom severity 
scale and on questionnaires of voice care knowledge in a group of teachers with self-
reported vocal problems receiving VFEs as treatment when compared to a VH group.  
VFEs have also been shown to improve perturbation, harmonics-to-noise ratio (HNR), 
perceived voice quality, and size and speed of pitch change in primary teachers with 
muscle tension dysphonia (MTD) (Nguyen & Kenny 2009).  The Nguyen (2009) study 
was a single-blinded randomized controlled trial that compared a “full exercise” (FE) 
group to a “partial exercise” (PE) control group.  The FE group completed VFEs with a 
modification of the vowel /o/ to the Vietnamese vowel /ô/, which is slightly higher than 
the English vowel /o/.  The exercise regimen and practice schedule were otherwise 
equivalent to VFEs as described by Stemple et al. (1994).  The PE group completed only 
the initial warm up exercise /i/ two times twice daily.  While both the PE and the FE 
groups improved somewhat, more subjects in the FE group experienced positive change 
and this group also enjoyed a higher magnitude of change.  Additionally, the FE group 
participants demonstrated positive change on a greater variety of outcome measures.  
This indicates that a reduced dose of VFEs, as achieved by performing only one of the 
four exercises, was insufficient in comparison to the full VFE protocol.  Teixeira and 
Behlau (2015) compared the effectiveness of VFEs and voice amplification (VA) in a 
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six-week therapy regimen for teachers with behavioral dysphonia.  They found that both 
the VFE and the VA groups demonstrated positive outcomes on measures of self-rated 
dysphonia in comparison to the control group.  However, the VFE group also showed 
improvement in auditory-perceptual evaluation, laryngeal status, and acoustic analysis 
outcome measures.  The authors concluded that VFEs effectively treat behavioral 
dysphonia in teachers, but that VA is really only effective as a preventative measure, 
while lack of intervention leads to worsening the disorder.   
Ziegler, Gillespie, and Abbott (2010) sum up the literature on the use of VFEs as 
a tool for intervention in teachers with disordered voice by pointing out that VFEs in 
isolation have treatment value for this population.  The benefits are greatest when the 
program is delivered within the context of individual therapy sessions where both the 
clinician and client are well-trained.  This conclusion was based on comparing efficacy 
studies of VFEs in disordered voice to a study by Pasa, Oates, and Dacakis (2007) which, 
contrary to the majority of research, found that a VH group of teachers with self-reported 
vocal abuse and voice symptoms improved more on outcome measures of voice 
characteristics and voice knowledge than a VFE group.  These findings have been largely 
attributed to the study’s methodology, which taught VFEs in a group setting and greatly 
reduced exposure to clinician input by limiting the number of sessions and eliminating 
one-on-one therapy (Ziegler et al., 2010).  This may indicate that reduced exposure to 
VFEs is less effective than the traditional dose.  The combined evidence elucidated by 
Ziegler et al. (2010) also suggested that VFEs are most effective when delivered in 
combination with other treatment approaches (for example VH counseling), although it is 
difficult in these cases to determine what portion of the outcome should be credited to 
 	 12	
VFEs and what portion should be attributed to other therapy techniques.  It seems 
reasonable to suspect that the benefits of VFEs are augmented by combined treatments 
since healthier vocal fold mucosa likely makes for a more efficient physiologic system.  
VFEs have also proven successful in treating hyperfunctional disorders such as 
contact granulomas.  Patel, Pickering, Stemple, and Donohue (2012) evaluated changes 
in vocal fold vibration and voice production in a single-subject before-after prospective 
study.  A six-week VFE protocol was conducted in a 51-year-old male with a unilateral 
contact granuloma.  While stroboscopic, acoustic, aerodynamic, and audioperceptual 
measures were minimally informative, high-speed digital imaging demonstrated 
improved efficiency of vocal function, vibratory motion, glottis closure, and impact 
stress.  The authors concluded that there is evidence to suggest that therapy techniques 
using semi-occluded vocal tract techniques (such as VFEs) are useful in treating contact 
granulomas.  
In individuals with presbylaryngeus (or aging larynx), statistically significant 
improvements on physiologic measures have been reported in a variety of research 
studies.  Gorman, Weinrich, Lee, and Stemple (2008) observed increased MPT and 
improved aerodynamic measures indicating reduced translaryngeal flow, better glottal 
closure, and increased subglottic pressure following completion of a VFE regimen in 
participants diagnosed with presbylaryngeus.  In 2008, Berg, Hapner, Klein, and Johns 
found improvement in Voice-Related Quality of Life (VRQoL) scores in individuals with 
age-related dysphonia after four sessions (five months) of voice intervention including 
vocal hygiene, resonant voice, and VFEs in comparison to a control group.  Average 
improvement on the VRQoL was 19 points for the experimental group and only one point 
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for the control group.  Furthermore, subjects in the experimental group who were 
described as “adherent” demonstrated better improvement (24 points on the VRQoL) in 
comparison to those who were “partially adherent” (improvement of 15 points).  This 
indicates that lower doses of VFEs completed by partially adherent participants 
attenuated positive outcomes.  Tanner, Sauder, Thibeault, Dromey, and Smith (2010) 
examined treatment responses in 79-year-old male monozygotic twins with vocal fold 
bowing to identify genetic and environmental factors associated with age related change 
and treatment response in a longitudinal, descriptive case study.  After surgical 
intervention, VFEs resulted in improved VHI scores and glottal closure, although 
dysphonia remained severe in both cases.  Intervention outcomes for each twin differed, 
possibly as a result of confounding factors such as differences in voice use and overall 
health.  VFEs have also yielded improved VHI scores, reduced self-rated vocal effort and 
severity, and reduced overall severity, breathiness, and strain in a pre-to-post test quasi-
experimental study of elderly patients with presbylaryngues (Sauder, Roy, Tanner, Houtz, 
& Smith, 2010).  Tay, Phyland, and Oates (2012) found that a group of singers over 65 
years of age who used VFEs improved on acoustic measures, MPT, and reduced their 
overall vocal roughness in comparison to a non-treatment group.  Ziegler, Abbot, Johns, 
Klein, and Hapner (2014) found improved scores on the VRQoL in a VFE group as 
compared to a non-treatment control group.  A retrospective study by Kaneko, Hirano, 
Tateya, Kishimoto, Hiwatashi, Fujiu-Kurachi, and Ito (2015) examined 16 participants 
with vocal fold atrophy who completed a six-week VFE protocol and compared them to a 
historical control group of similar age range.  While the historical control group made no 
improvements, the VFE group demonstrated significant improvement on the Grade, 
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Roughness, Breathiness, Asthenia, Strain (GRBAS) scale, MPT, jitter, VHI, normalized 
mucosal wave amplitude, and normalized glottal gap.  Bowing index did not change 
significantly, and the study concluded that despite the lack of change on this outcome 
measure, VFEs may improve muscular function during voicing, thereby yielding 
improvements in subjective, objective, and self-assessment measures.  There is evidence 
to suggest that VFEs successfully treat presbylaryngeus or age-related vocal fold atrophy.     
VFEs have also been attempted with transgender populations.  In 2013, Gelfer 
and Van Dong explored the voice outcomes for male-to-female (MTF) transgender 
clients seeking voice feminization when treated with symptomatic voice therapy in 
combination with VFEs for six weeks.  Three MTF transgender participants provided 
voice samples that were compared to male and female control samples.  While VFEs did 
not appear to improve acoustic or perceptual outcome measures, the participants 
themselves reported satisfaction with the addition of VFEs into their treatment.   
Finally, VFEs may be used in cases of laryngeal injury, as demonstrated by 
Sharma, Martin, and Pracy (2009).  This case study examined an individual with a 
laryngeal fracture secondary to penetrating shrapnel injury, which was surgically 
repaired.  Voice improvement was rapid using a three-month VFE protocol with practice 
twice daily, and MPT more than doubled in length.  Thus, in this case study, VFEs 
improved voice after laryngeal injury.     
VFEs As a Standard of Care        
More recently, VFEs have served as a therapeutic benchmark against which to 
compare alternative voice interventions.  One such example is a study completed by 
Pedrosa, Pontes, Pontes, Behlau, and Peccin (2015) which compared VFEs to a new 
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voice treatment program entitled the Comprehensive Voice Rehabilitation Program 
(CVRP).  In this randomized blinded clinical trial, 80 professional voice users with 
functional dysphonia were randomized into a CVRP or VFE group and completed six 
treatment sessions.  Both groups improved on all outcome measures, which included self-
assessment, perceptual evaluation of voice quality, and laryngeal examination.  The 
authors concluded that both programs were effective in treating functional dysphonia in 
professional voice users.  A second example is a randomized controlled trial completed 
by Kapsner-Smith, Hunter, Kirkham, Cox, and Titze in 2015, which compared phonation 
through flow-resistant tubes (FRT) to VFEs as an established therapeutic technique.  
Twenty participants with dysphonia were assigned to one of four groups: immediate 
FRT, immediate VFE, delayed FRT, or delayed VFE.  Both groups improved relative to 
the control groups and the authors concluded that both treatment techniques may improve 
voice quality of life in people with dysphonia.  
In sum, the literature on VFEs as described by Stemple et al. (1994) demonstrates 
that VFEs are effective in the normal voice and in the highly trained voice (e.g. opera 
singers).  This technique also improves disordered voice in individuals with functional 
dysphonia, contact granulomas, presbylaryngeus (i.e., vocal fold atrophy), and muscle 
tension dysphonia.  Gains on subjective, objective, and self-assessment measures have 
been systematically observed.  Therefore, VFE effectiveness can be demonstrated in a 
variety of populations and for many vocal parameters.    
VFE Dose 
The literature with respect to optimal VFE dosing is sparse, but a few speculations 
can be extrapolated from the preexisting research.  The study by Stemple et al. (1994) 
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looked at VFEs in adult women with normal voice.  Part of the study’s findings indicated 
that for the experimental group, the greatest gain in weekly phonation times occurred 
between weeks one and two. After that point in time, the majority of the participants’ 
times plateaued, since they had met their MPT goal based on individual physiologic 
capacity.  Since the participants in the experimental group achieved their goals so 
quickly, yet completed a six-week protocol, this may indicate that only a low dose of 
VFEs is necessary to produce positive results in the normal voice.  However, it would be 
difficult to draw conclusions regarding maintenance of those improvements without 
further research of low dose-response relationships.       
As with any intervention, adherence to treatment is paramount.  In a comparison 
study examining the effects of monitored versus unmonitored VFEs in adult women with 
normal voice, Ellis & Beltyukova (2011) found that both groups performing VFEs 
significantly increased their MPT and maximum phonational frequency range (MPFR).  
However, the group monitored for compliance via audio recordings improved 
significantly more than the unmonitored group.  Since poor compliance most likely 
meant alterations in dosage, it seems that adhering more strictly to the prescribed dosage 
led to greater improvement in normal voice.  Thus, reduction of VFE exposure may 
diminish outcomes in normal voice.  This conclusion partially contradicts the idea that 
low exposures of VFEs may be sufficient in individuals with normal voice.  However, 
given the complex relationship among dose, dosage, and compliance, a direct 
contradiction cannot be assumed.        
The Pasa et al. (2007) study reduced the administered VFE dose by using a two 
hour group session with four group sessions over a period of ten weeks, thereby reducing 
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individual exposure to the clinician and resulting in suboptimal outcomes.  This study 
found that a VH group of teachers with self-reported vocal abuse and voice symptoms 
improved more on outcome measures of voice characteristics and voice knowledge than a 
VFE group.  This may indicate that reduced exposure to VFEs is less effective than the 
traditional dose in individuals with self-reported voice problems. 
A case study by Radhakrishnan and Scheidt (2012) found that modifying the VFE 
regimen resulted in post-treatment improvement on perceptual, objective, and self-
perceptual outcome measures in a participant with presbylaryngeus.  In that retrospective, 
single case report, the patient was unable to achieve the posture required for VFEs and 
was unable to match pitch for the final adductory power exercise.  The VFE posture was 
therefore modified: the pitch glides and final low-impact power adductory exercises were 
performed on /o/.  Secondary to the participant’s difficulty with pitch matching, she was 
simply instructed to complete the final exercise by ascending in pitch slightly each time.  
While this may have modified the intensity of the VFE protocol by decreasing the 
complexity or accuracy required for each task, the frequency and amount of practice was 
kept constant at two times each twice daily.  Thus, it is important to consider the 
converging and diverging aspects of dose and intensity.  It is arguable that the 
Radhakrishnan and Sheidt (2012) study preserved VFE dose while modifying intensity 
and specificity in that they reduced the strenuousness of the intervention but not the 
amount.  However, changing aspects of any protocol may innately modify dose since, as 
Baker (2012) mentions, we cannot pinpoint the precise active ingredient(s) that make 
intervention effective.  For VFEs, the active ingredient is thought to be the semi-occluded 
vocal tract posture, which heightens source-filter interaction allowing for greater 
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economy of voice in terms of collision stress or vibration dose (Titze, 2006).  Thus, it 
would be important to question whether modifying VFE technique to use the vowel /o/ 
for the series of exercises significantly compromises an active therapeutic ingredient.  If 
so, perhaps lower doses of VFEs are effective in individuals with vocal fold atrophy. 
In summary, there are no direct studies on dosage as it applies to VFEs.  The 
weak conclusions that can be drawn are as follows:  
1. Low doses of VFEs may be sufficient to improve the normal voice 
2. Low doses of VFEs may not improve the normal voice to the same extent that 
higher doses would. 
3. Low doses of VFEs may be insufficient to improve the disordered voice. 
4. Traditional doses of VFEs with modified intensity may be sufficient to 
improve the disordered voice.  
Other Voice Interventions and Dose 
While the literature on VFE dosage is sparse, information about dosing can also 
be gleaned from research exploring dose in other types of voice interventions.  These 
have primarily examined the effects of the Lee Silverman Voice Treatment (LSVT).  A 
comparison between VFEs and LSVT can be drawn because both interventions target the 
three subsystems of voice: respiration, phonation, and resonance.  LSVT is delivered in a 
high intensity format of four weekly sessions for four weeks plus additional daily 
homework.  LSVT delivery is referred to as intense dosage in terms of frequency of 
treatment, repetitions within sessions, and effort required for each task.  Intensive training 
is thought to recalibrate the patient’s internal feedback system and allow the person to 
internally cue appropriate loudness during speech (i.e., result in long-term functional 
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changes in behavior).  Furthermore, intense training of a single target is thought to result 
in cross-system improvements (Fox & Ramig, 2006).   
Various alterations have been made to the LSVT protocol.  Spielman, Ramig, 
Mahler, Halpern, and Gavin (2007) examined the effects of an extended LSVT program 
(LSVT-X) in 12 participants with idiopathic Parkinson’s disease.  Treatment was 
delivered in one-hour sessions twice weekly for eight weeks and outcomes were 
compared to a historical group who had completed the traditional dose of one-hour 
sessions four times weekly for four weeks.  While both groups enjoyed the same amount 
of direct time with the clinician, the LSVT-X group completed far more homework with 
a different distribution of treatment sessions and greater expanses of time between 
treatment sessions.  Thus, intensity was reduced in the LSVT-X group in some ways, but 
dosage may have actually been greater in that there were more home practice sessions.  
Results indicated that both groups had comparable increases in vocal SPL and both 
groups maintained these improvements at six months.  Both groups had improved VHI 
scores and listener ratings.  Interestingly, interviews with the clinicians who delivered 
LSVT-X indicated that treatment seemed less efficient in terms of learning the target.  
The authors speculated that more time was spent in the pre-learning stage for individuals 
in the extended treatment group.  However, data in the LSVT-X group trended toward 
increasing vocal SPL from post treatment measures to one-month follow up, indicating 
that the extended treatment may have established better motor patterns that continued to 
improve even after treatment ended.  
Another study by Wohlert (2004) examined the efficacy of LSVT in various 
formats.  Participants with Parkinson’s disease were divided into three groups.  One 
 	 20	
group received the traditional treatment (four times a week for four weeks), another 
received treatment twice a week for eight weeks, and the last group received treatment 
twice a week for four weeks.  They found that vocal SPL, MPT, and pitch range 
improved but that at the three-month follow up most of these gains were substantially 
reduced for all groups.  The authors concluded that the schedule of treatment did not 
appear to have a predictable impact on outcomes, although statistical analyses were not 
completed.  These results would indicate that halving the dosage of LSVT led to 
comparable improvement, since one of the groups received only two weekly sessions for 
four weeks.  However, these results have not carried a great deal of weight due to 
methodological errors such as incomplete randomization and differences in data 
collection from other LSVT studies (Spielman et al., 2007).   
 A study by Searl, Wilson, Haring, Dietsch, Lyons, and Pahwa (2011) attempted to 
demonstrate the feasibility of LSVT LOUD in a group format for 15 individuals with 
Parkinson’s Disease.  Participants received 90-minute sessions led by three clinicians 
weekly for eight weeks.  Daily homework was completed in larger amounts than in 
traditional LSVT delivery.  Statistically significant improvements for vocal intensity, 
maximum fundamental frequency, fundamental frequency range, and VHI scores were 
observed.  The increase in SPL for group LSVT was slightly reduced compared to 
traditional delivery, though compliance with homework was strongly correlated to 
changes in loudness.  Extended treatment may have reduced motivation or compliance 
with homework.  Still, 80% of participants were judged as louder after completing 
treatment.  The authors concluded that it is feasible to complete LSVT in a group format 
with some modifications.    
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 It is important to note that while LSVT has been shown to be effective in 
improving vocal SPL in patients with Parkinson’s disease, intensity of treatment alone 
was insufficient to produce positive outcomes.  Several studies have compared LSVT to 
other interventions such as respiratory effort treatment delivered in the same format 
(intensity) and have found that the latter does not result in similar benefits (Baumgartner, 
Sapir, & Ramig, 2001; Ramig & Countryman, 1995; Ramig, Countryman, O’Brien, 
Hoehn, & Thompson, 1996).  Thus, intensity alone is insufficient and, as Baker (2012) 
states, active treatment ingredients must be identified.  She further argues that “…the 
target itself could influence just how many sessions are required, and, ultimately, the total 
intervention duration” (Baker, 2012, p. 404).   
Nonetheless, intense intervention may play an important role in optimizing 
outcomes.  Some voice clinicians have even suggested a type of voice boot camp as an 
intensive, short-term program for people with chronic dysphonia (Patel, Bless, & 
Thibeault, 2011).  The program involves multiple sessions a day and incorporates a 
variety of therapeutic approaches to achieve maximum gain in a matter of days.  Thus far, 
outcome studies for these types of programs have not been completed.  Verdolini-
Marston, Lessac, Glaze, and Caldwell (1995) described the effects of an intensive model 
of treatment for confidential voice and resonant voice therapy programs in individuals 
with vocal nodules.  Treatment was delivered in a total of eight individual sessions over a 
two-week period.  All participants in both experimental groups improved on one or more 
outcome measures post-treatment, while none of the participants in the control group 
demonstrated improvement.  The authors indicated that compliance with homework was 
a predictor of success in both experimental groups, but noted that it was “not definitive 
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whether the success of treatment was related to the type of treatment technique 
participants received (i.e., ingredient of treatment) or the dosage (i.e., intensive vs. 
standard)” (Verdolini-Marston et al., 1995, pg. 652.e41).  The authors then called for a 
standardization of treatment received between individuals.          
In an evaluation of the impact of intensive treatment on functional, service, and 
well-being outcome measures in clients with functional dysphonia, Wenke, Stabler, 
Walton, Coman, Lawrie, O’Neill, Theodoros, and Cardell (2014) compared intense 
treatment to standard treatment.  In this study, an intense treatment group (n = 7) received 
four, one-hour sessions weekly for two weeks, while a standard treatment group (n = 9) 
received weekly one-hour sessions for eight weeks.  Both groups received vocal hygiene 
education and a total of eight hours of therapy, which was individualized and consisted of 
evidence-based behavioral techniques.  Results indicated higher satisfaction and greater 
VHI improvement after intense treatment, as well as improved attendance.  Furthermore, 
the intense treatment group demonstrated continued improvement at follow-up, indicating 
that motor learning continued in the absence of rehabilitation.  This is consistent with the 
Spielman et al. (2007) finding that an experimental group receiving LSVT-X improved 
from post-treatment to follow-up.  Wenke et al. noted that intense treatment may have 
“enhanced motor learning and provided greater opportunity for the individual to 
consolidate the learnt vocal techniques and vocal hygiene behaviors” (Wenke et al, 2014 
p. 652.e40).  Conversely, the standard treatment group reported wanting additional 
practice or more therapy, indicating that they did not feel that they had mastered the voice 
techniques.  In corroboration with this sentiment, the treating clinician indicated that 
standard group participants spent more time revising acquisition of learned vocal 
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strategies, indicative of a “pre-practice” phase where the patient aquires basic knowledge 
of the task through conscious attention.  This is also consistent with the LSVT-X 
experimental group from the Spielman et al. (2007) study.  Because treatment was 
distributed over more time, the extended treatment group may have spent more time in 
the pre-practice stage.  This is important to therapeutic outcomes because the principles 
of motor learning dictate that practice closely approximates the desired target.  If vocal 
techniques take longer to consolidate, then practice may not closely resemble the desired 
behavior.  Ultimately, the authors of the Wenke et al. (2014) study concluded that 
intensive treatment had potential to improve healthcare cost efficiency and satisfaction 
for both client and clinician by improving attendance and treatment completion, 
ultimately leading to better outcomes.  However, as with the Verdolini-Marston et al. 
(1995) study, no standardization of treatment was implemented.  Thus, there is evidence 
to suggest that intense treatment can lead to better outcomes with greater efficiency, but 
this is not explicitly linked to dose.  Treatment delivery, compliance, motivation, and a 
host of other factors also play important roles in patient outcomes.   
Principles of Sensory Motor Learning and Dose 
Increasing the frequency and amount of therapy may facilitate learning at the 
neuronal level, as postulated by Pulvermuller and Berthier (2008).  This study found that 
longer therapy sessions in a short time period were more efficient than therapy distributed 
over longer times.  Support for this idea can also be found in the principles of motor 
learning, which dictate that repetition is necessary to induce lasting change and that it 
may take several days of training to establish underlying neural changes.  Higher 
intensity stimulation can induce long-term potentiation that makes the behavior resistant 
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to decay in the absence of training (Kleim & Jones, 2008).  This result may have been 
demonstrated by the LSVT-X group (Spielman et al., 2007) and the intense treatment 
group (Wenke et al., 2014).  Motor skills are learned both online (i.e., during training) 
and offline (i.e., after training ends).  The latter is important for skill stabilization and 
consolidation, whereby offline behavioral skill improvements occur after end of practice.  
Consolidation, in turn, is vital for long-term retention of motor skills (Dayan & Cohen, 
2011).  Long-term retention has important implications for maintenance of therapeutic 
effects and follow-up data collected for research.  It is important to note that rehearsal of 
procedural information in short-term memory promotes formation and consolidation of 
information for the long-term, highlighting the importance of practice methods and 
dosage.  For example, principles of motor learning state that frequently repeated motor 
patterns reinforce neural patterns, and that blocked practice is important during initial 
skill acquisition (Classen, Liepert, Wise, Hallett, & Cohen, 1998).  So long-term 
maintenance is partly dependent on how motor skills are acquired to begin with, and 
acquisition has everything to do with practice, compliance, dose, intensity, and service-
delivery of treatment.  
In summary, there are few studies on treatment intensity and dose in intervention 
for voice.  The weak conclusions that can be drawn are as follows:  
1. There is literature to support intense treatment in terms of efficiency, improved 
outcomes, compliance, patient satisfaction, neuroplasticity, and maintenance.  
2. Efficacy of treatment is dependent both on dose and intensity as well as on 
active therapeutic ingredients.  
3. Dose and intensity have not been systematically differentiated or studied. 
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4. Toxic effects of intense voice treatment have not yet been defined in the 
literature. 
Research Hypotheses 
1. Higher dosage of home practice VFEs will lead to faster goal attainment in 
normal voice. 
2. All dosage groups will improve in comparison to baseline and attain physiologic 
VFE MPT goals.  This hypothesis is based on the fact that in the Stemple et al 
(1994) study on VFEs in young adult females with normal voice, nearly all 
subjects plateaued in terms of MPT after two weeks of practice.  In a six-week 
regimen like the one used in this study, it is reasonable to expect that even lower 
doses of VFEs will result in goal attainment. 
3. The high dosage group will demonstrate better maintenance once month post-
treatment.  This hypothesis is based on research completed in another intervention 
that targets the three subsystems of voice, LSVT.  In the Spielman et al. (2007) 
study, an extended protocol with increased home practice resulted in data at one-
month follow-up that trended toward increasing vocal SPL in comparison to post 
treatment measures.  The authors speculated that better motor patterns may have 
been established that continued to improve even in the absence of treatment.  
Chapter Summary     
 Chapter two served to review pertinent literature regarding VFEs and dosage for 
voice interventions.  In essence, the ideal dose of VFEs is simply unknown because, like 
many interventions for voice, it has not been thoroughly investigated.  Chapter three will 
introduce the methods used to help address this problem.  
 	 26	
Chapter Three: Methodology 
All recruitment, intervention, and data collection procedures were approved by the 
Institutional Review Board (IRB) at the University of Kentucky (UK). 
Participants 
A total of 30 female participants with normal voice were recruited from the 
University of Kentucky College of Health Sciences (see Appendix A).  Participants met 
the following inclusion criteria: female, between 18 and 25 years (>18 and <26), non-
smokers, and hearing within normal limits.  A year or more of classical vocal training, 
history of uncontrolled asthma, and presence of vocal fold pathology identified by 
laryngeal examination constituted exclusion from the study (see Appendix C).  Twenty-
eight participants were enrolled and completed baseline assessment protocol.  In the first 
week, eight participants withdrew from the study but were replaced with new recruits.  A 
total of 28 participants completed the study.    
During the first session, consent was obtained using forms approved by the UK 
IRB (see Appendix B).  All participants were briefly educated on abusive vocal behaviors 
and agreed to abstain from these behaviors for the duration of the study.     
Exercise Procedure 
Participants were placed randomly into one of three groups: low exposure, 
typical, or high exposure.  All groups completed VFEs twice daily, once in the morning 
and once in the evening, seven days per week for six weeks (see Appendix G).  The low 
exposure group did all exercises one time through.  The typical exposure group 
performed all exercises twice each.  The high exposure group completed all exercises 
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four times each.  Based on the participant’s vital capacity, each individual in all three 
experimental groups was given a goal for MPT (VC/ 80mL/s = MPT goal).   
Training.  After baseline measures were obtained, each participant met with a 
research assistant, who taught them VFEs as described by Stemple et al. (1994).  Training 
of all research assistants was done prior to beginning the study.  Training was formal and 
conducted by a specialist in voice disorders with extensive experience training and 
performing VFEs.  The first training session established technique using a group format 
with breaks for individual coaching.  The next training session allowed for individual 
practice with an experienced clinician.  The third training session consisted of review and 
practice with a second year graduate student with experience performing and teaching 
VFEs.  Twenty percent of all research assistant-conducted sessions with study 
participants were monitored by an expert in voice.  An additional 20% of all sessions 
were monitored by a second year graduate student with experience with VFEs. 
Once each participant had learned VFEs from the trained research assistant, an 
expert in voice joined the session to solidify technique and obtain MPT baselines.  
Participants were then provided with a Dropbox link containing a face video specific to 
their dosage group that provided them with instructions, pitches, and walked them 
through home practice.  Additionally, each participant received home practice MPT score 
sheets specific to her dosage assignment.   
Compliance and home practice.  Exercises were completed at home with 
frequency dictated by group placement using the provided face videos.  Compliance was 
monitored using practice record sheets, which participants brought to weekly check-ins.  
Participants received reminders to practice via email twice a day.   
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Weekly check-ins.  Participants returned weekly for check-ins with a research 
assistant, who recorded MPTs and adjusted technique as necessary with the help of 
supervising clinicians.  A total of seven sessions were attended, for a total of six weeks of 
VFEs.     
Outcome Measures/ Assessment Parameters 
Based on the Committee on Phoniatrics of the European Laryngological Society 
recommendation that self-assessment, auditory-perceptual, stroboscopic, acoustic, and 
aerodynamic parameters be included in a functional assessment of voice, all of these 
parameters were included (Speyer, 2008).  These assessments provided a variety of 
outcome measures, however the primary outcome measure was MPT.  
Baseline measures were obtained prior to intervention and included patient self-
assessment (VRQoL, see Appendix F), audio-perceptual assessment (CAPE-V, see 
Appendix E) completed by a clinician specialized in voice, stroboscopic examination, 
acoustic measures (MPT, jitter percent, shimmer dB, noise to harmonics ratio, frequency 
range), and aerodynamic measures (vital capacity, subglottic pressure/ mean peak air 
pressure, laryngeal airflow rate, laryngeal airway resistance/ aerodynamic resistance, see 
Appendix D).  Participants also provided VFE MPTs using the appropriate mouth 
postures consistent with a semi-occluded vocal tract.   
 Participants attended weekly check-ins for six weeks subsequent to learning 
VFEs.  At each check-in, they completed the VRQoL to assist in monitoring for toxic 
effects.  VFE MPTs (using semi-occluded mouth postures) were recorded at weekly 
check-ins.  After three weeks of exercises, stroboscopic examination was performed to 
verify presence/absence of observable toxic effects. 
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 Post-experimental measures were obtained after six weeks of exercises and 
included all parameters obtained at baseline including VFE MPTs.  Participants 
discontinued exercise practice and weekly check-ins at this time. 
 Four weeks after protocol completion, participants returned for their one-month 
follow-ups and all assessment parameters obtained at baseline were collected again, 
including VFE MPTs. 
Chapter Summary 
 Chapter three outlined the methods used to contribute to the literature on dosage 
as it applies to use of VFEs in normal voice.  Following in chapter four are the results.  
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Chapter Four: Results  
Demographics 
A total of 28 female subjects between the ages of 18 and 25 were recruited from 
the University of Kentucky College of Health Sciences and enrolled in this study.  Eight 
participants discontinued their participation but were replaced with new recruits.  A total 
of 28 subjects completed the study.  Subjects were non-smokers with normal voice.  Each 
underwent a full voice assessment before and after a six-week VFE intervention protocol.  
Subjects returned one month post-intervention for an additional voice assessment.  
During the six-week intervention period, each participant completed home practice twice 
daily (morning and evening) using a practice log to record the VFE MPT results.  The 
number of repetitions during home practice was determined by the participant’s random 
group assignment.  The low dose group did each exercise once, the traditional dose group 
completed each exercise twice, and the high dose group performed each exercise four 
times.  Each subject attended a weekly check-in to monitor compliance, provide VFE 
MPTs, and turn in practice logs.  Weekly average phonation times were calculated for 
each participant (see Appendix I).  Table 4.1 presents the characteristics of the low, 
traditional, and high dose groups for the variable of age.  In the low dose group, ages 
ranged from 18 to 25; average age was 21.10 and median age was 20.  In the traditional 
dose group, ages ranged from 18 to 24; average age was 21.56 and median age was 21.  
In the high dose group, ages ranged from 18 to 25; mean age was 20.60 and median age 
was 20.5.  
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Table 4.1: Demographics 
Group Age Mean Age Median Age Standard 
Deviation 
 
Low Dose 
18, 19, 19, 20, 20, 
21, 23, 25, 25 
 
21.10 
 
20.00 
 
2.619 
 
Traditional Dose 
18, 10, 21, 21, 21, 
22, 23, 24, 24 
 
21.56 
 
21.00 
 
1.944 
 
High Dose 
18, 18, 19, 19, 20, 
21, 21, 22, 23, 25 
 
20.60 
 
20.5 
 
2.271 
 
Groups.  The low dose group consisted of nine participants, two of whom 
discontinued their participation.  The traditional dose group contained nine participants, 
one of whom discontinued her participation.  The high dose group contained ten 
participants, five of whom discontinued their participation.  This resulted in a withdrawal 
rate of 22%, 11%, and 50% for the low, traditional, and high dosage groups, respectively.  
Subjects who withdrew from the study were replaced by new recruits the subsequent 
week.  Because intervention had already begun and subjects could not be completely re-
randomized, replacement was completed by filling vacancies in each group as needed to 
maintain equal numbers across groups.  This information is represented in Table 4.2, 
which provides dosage group descriptions, number of participants, and the number of 
participants who discontinued their participation.    
Table 4.2: Dosage Assignments 
Group No. of Participants Discontinuing Participants 
Low Dose  
VFEs one time each, twice daily 
n = 9 2/ 9 = 22% 
Traditional Dose 
VFEs two times each, twice daily 
n = 9 1/9 = 11% 
High Dose  
VFEs four times each, twice daily 
n = 10 5/10 = 50% 
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Withdrawal questionnaires.  Upon discontinuation of this study, participants 
were asked to complete a questionnaire regarding rationale for withdrawal (see Appendix 
H).  Of the eight participants who withdrew from the study, six completed and returned 
the questionnaire.  One of the questions probed the former participants’ experience with 
laryngeal examination by asking what degree of discomfort they experienced when being 
scoped.  Four participants reported no discomfort, one reported mild discomfort, and one 
reported extreme discomfort.  The remainder of the questionnaire addressed the reason 
for withdrawal.  Five former subjects reported that the time commitment involved in the 
study was too great.  Two reported difficulty with mastering the required technique for 
VFEs.  One reported that a personal matter demanded her withdrawal.  One participant in 
the high dose group reported pain, soreness, and/or fatigue following exercises.  She was 
further interviewed by the researcher but refused laryngeal examination.  The results of 
the withdrawal questionnaire are detailed below in Table 4.3. 
Table 4.3: Withdrawal Questionnaire Results    
 Subject Report Subject Group 
Strobe 
tolerance 
4 reported no discomfort 
1 reported mild discomfort 
1 reported extreme discomfort  
2 Low, 2 High 
1 Traditional 
1 High 
Reason for 
discontinuation 
5 reported excessive time commitment  
2 reported difficulty with VFE technique 
1 reported a personal matter 
1 reported pain/ soreness/ fatigue  
1 Low, 1 Traditional, 3 High  
1 Traditional, 1 High 
1 Low 
1 High 
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Baseline Measures 
 A series of between subjects one-way ANOVAs demonstrates equivalence 
between groups at baseline for a number of acoustic, aerodynamic, auditory-perceptual, 
and self-assessment variables.  These variables include age, airflow, subglottic pressure, 
laryngeal airway resistance, range, jitter, shimmer, noise-to-harmonics ratio, acoustic 
maximum phonation time, VFE maximum phonation time, CAPE-V scores (overall, 
roughness, breathiness, strain, pitch, loudness), and VRQoL self-ratings.   
A significance value of .05 (Alpha = 0.05, Power = 80%) was used based on a 
power analysis completed a priori.  The resulting p-values for each of these variables are 
listed in Table 4.4, and indicate that groups differed at baseline only in terms of laryngeal 
airway resistance (LAR), p = .050.  However, the homogeneity of variance (Levene’s 
test) was also statistically significant (p = .002).  Therefore, to further examine this 
variable, two separate, more robust tests were completed: the Welch and the Brown-
Forsythe tests.  These tests found that groups were not significantly different in terms of 
LAR.  Additionally, a Games-Howell post-hoc test was performed to account for unequal 
variance and also resulted in non-significance (p = .996, p = .201, p = .208). 
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Table 4.4: One-Way ANOVAs for Baseline Measures 
 One way ANOVA 
p-value 
Welch Test Brown-Forsythe 
Test 
Age .666 .634 .667 
Airflow .533 .639 .532 
Psub .826 .813 .828 
LAR .050* .209 .085 
Range .866 .878 .867 
Jitter .271 .245 .264 
Shimmer .537 .527 .545 
NHR .872 .839 .869 
Acoustic MPT .263 .222 .286 
VFE MPT .636 .602 .640 
CAPE-V Overall .177 .276 .202 
CAPE-V Roughness .511 .601 .529 
CAPE-V Breathiness .290 .269 .313 
CAPE-V Strain .497 .571 .515 
CAPE-V Pitch .604 -- -- 
CAPE-V Loudness .953 .952 .953 
VRQoL .791 .713 .786 
* denotes statistically significant value (p ≤ .05) 
 
Outcome Measures 
Primary outcome measures.  The primary purpose of this investigation was to 
examine the effect of varying doses of VFE home practice on attainment of pre-
established MPT goals in individuals with normal voice production.  VFE MPT was 
collected at baseline, weekly during the VFE protocol, after six-week intervention, and at 
one-month follow-up.  Individual physiologic goals for VFE MPT were determined by 
dividing each participant’s forced expiratory volume by 80mL/s.  After data collection, 
average weekly VFE MPTs were calculated.  Percentage of goal attainment was 
calculated at baseline, after intervention, and at one-month follow-up.  Percentage point 
change was calculated for each subject using these three time points.  Change was 
calculated comparing baseline to post-intervention, post-intervention to follow-up, and 
baseline to follow-up.   
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In the low dose group, one of nine participants reached 80% of her physiologic 
goal, and this occurred at her one-month follow-up.  Average percentage point change 
between baseline and post-intervention for the low dose group was 16.44; median 
percentage point change was 10.00.  Average percentage point change post-intervention 
to one-month follow-up was -1.78; median was -3.00.  This indicates a decrease in VFE 
MPT during that time period.  Average percentage point change from baseline compared 
to one-month follow-up was 9.22; median change was 6.00.   
In the traditional dose group, three of nine participants achieved 80% of their 
respective physiologic goals.  Goal attainment for each of the three subjects occurred at 
check-in four, five, and seven, respectively.  Average percentage point change between 
baseline and post-intervention for the traditional dose group was 25.56; median 
percentage point change was 24.00.  Average percentage point change post-intervention 
to one-month follow-up was -10.89; median was -9.00.  This indicates a decrease in VFE 
MPT during that time period.  Average percentage point change from baseline compared 
to one-month follow-up was 14.67; median change was 15.00.   
In the high dose group, four of ten participants achieved 80% of their respective 
physiologic goals.  Goal attainment for each of the four subjects occurred at check-in 
two, five, five, and seven, respectively.  Average percentage point change between 
baseline and post-intervention for the high dose group was 33.30; median percentage 
point change was 30.00.  Average percentage point change post-intervention to one-
month follow-up was -16.00; median change was -15.00.  This indicates a decrease in 
VFE MPT during that time period.  Average percentage point change from baseline 
compared to one-month follow-up was 17.50; median change was 14.00.   
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The hypothesis that higher dosages of home practice of VFEs would lead to faster 
goal attainment in normal voice was proved.  The hypothesis that all dosage groups 
would improve in comparison to baseline and attain physiologic VFE MPT goal was not 
proved.  Although all subjects improved their MPT from baseline, many did not reach 
physiologic goal.  The hypothesis that the high dose group would demonstrate better 
maintenance at follow-up was not proved.  
Acoustic MPT was also collected at baseline, after intervention, and at one-month 
follow up.  Percentage point change was calculated in the same manner as for VFE MPT.  
Average percentage point change between baseline and post-intervention for the low dose 
group was 5.56; median percentage point change was 5.00.  Average percentage point 
change post-intervention to one-month follow-up was -2.78; median change was -2.00.  
This indicates a decrease in acoustic MPT during that time period.  Average percentage 
point change from baseline compared to one-month follow-up was 2.78; median change 
was 2.00.   
Average percentage point change between baseline and post-intervention for the 
traditional dose group was 5.78; median percentage point change was 6.00.  Average 
percentage point change post-intervention to one-month follow-up was -0.4; median 
change was -1.00.  This indicates a decrease in acoustic MPT during that time period.  
Average percentage point change from baseline compared to one-month follow-up was 
5.33; median change was 5.00.   
Average percentage point change between baseline and post-intervention for the 
high dose group was 5.43; median percentage point change was 7.00.  Average 
percentage point change post-intervention to one-month follow-up was -3.00; median 
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was -1.00.  This indicates a decrease in acoustic MPT during that time period.  Average 
percentage point change from baseline compared to one-month follow-up was 0.57; 
median change was 2.00.  The percentage point changes for acoustic and VFE MPT are 
provided in Table 4.5 for each dosage group.  
Table 4.5: Primary Outcome Measures: VFE MPT & Acoustic MPT 
VFE MPT 
 Low Dose Traditional Dose High Dose 
Number of 
participants reaching 
80% of goal 
 
Week goal achieved 
 
 
1 of 9 
 
At 1-mo. follow-up 
 
 
3 of 9 
 
4, 5, 7 
 
 
4 of 10 
 
2, 5, 5, 7 
Percentage point 
change pre-post 
Average 
Median 
 
 
16.44 
10.00 
 
 
25.56 
24.00 
 
 
33.30 
30.00 
Percentage point 
change post-1 mo. 
follow-up 
Average 
Median 
 
 
 
-1.78 
-3.00 
 
 
 
-10.89 
-9.00 
 
 
 
-16.00 
-15.00 
Percentage point 
change pre-1 mo. 
follow-up 
Average 
Median 
 
 
 
9.22 
6.00 
 
 
 
14.67 
15.00 
 
 
 
17.50 
14.00 
Acoustic VFE 
Percentage point 
change pre-post 
Average 
Median 
 
 
5.56 
5.00 
 
 
5.78 
6.00 
 
 
5.43 
7.00 
Percentage point 
change post-1 mo. 
follow-up 
Average 
Median 
 
 
 
-2.78 
-2.00 
 
 
 
-0.44 
-1.00 
 
 
 
-3.00 
-1.00 
Percentage point 
change pre-1 mo. 
follow-up 
Average 
Median 
 
 
 
2.78 
2.00 
 
 
 
5.33 
5.00 
 
 
 
0.57 
2.00 
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 Paired sample t-tests were used to examine change in primary outcome measures 
between each of the data collection time points using a significance value of .05.  In the 
low dose group, acoustic MPT was significantly different baseline to post-intervention.  
VFE MPT was significantly different between baseline and post-intervention and also 
between baseline and one-month follow-up.  In the traditional dose group, acoustic MPT 
was significantly different between baseline and post-intervention.  VFE MPT was 
significantly different across all three data collection time points.  For the high dose 
group, acoustic MPT was not significantly different at any time point, but VFE MPT was 
significantly different across all data collection time points.  Resulting p-values from the 
data analysis can be viewed in Table 4.6.   
Table 4.6: Paired Sample T-Tests for Primary Outcome Measures 
Low Dose Pre-post p-value Post-month p-value Pre-month p-value 
Acoustic MPT .035* .138 .356 
VFE MPT .004* .347 .039* 
Traditional Dose Pre-post p-value Post-month p-value Pre-month p-value 
Acoustic MPT .029* .803 .096 
VFE MPT .001* .001* .014* 
High Dose Pre-post p-value Post-month p-value Pre-month p-value 
Acoustic MPT .148 .330 .811 
VFE MPT .001* .003* .001* 
* denotes statistically significant value (p ≤ .05) 
 
Toxicity.  A secondary purpose of this investigation was to observe the presence 
or absence of toxic effects on the vocal folds as a potential result of increased VFE home 
practice.  Each subject underwent laryngeal examination and stroboscopy at baseline, 
after three weeks of VFEs, after intervention at six weeks, and at one-month follow-up.  
Toxicity was defined as visualization of any vocal fold pathology, erythema, or edema.  
No signs of toxicity were identified at any data collection point.  Additionally, each 
participant completed the VRQoL weekly to monitor for substantial changes in self-
 	 39	
ratings of voice.  One subject in the high dose group withdrew from the study in the first 
week, complaining of vocal fatigue and throat soreness.  That subject completed an 
interview and a withdrawal questionnaire but refused laryngeal examination.           
Secondary outcome measures.  Finally, this study evaluated a variety of 
secondary outcome measures including self-assessment, auditory-perceptual, 
aerodynamic, and acoustic measures before and after VFE intervention.  Secondary 
outcome measures included airflow, subglottic pressure, laryngeal airway resistance, 
range, jitter, shimmer, noise-to-harmonics ratio (NHR), CAPE-V scores (overall, 
roughness, breathiness, strain, loudness, pitch), and VRQoL self-ratings.  A series of 
paired sample t-tests was performed for the variety of variables representing secondary 
outcome measures for comparisons between each of the data collection time points.   
For the low dose group, CAPE-V loudness was significantly different between 
baseline and post-intervention.  Subglottic pressure was significantly different between 
post-intervention and one-month follow-up.  VRQoL self-ratings were significantly 
different between baseline and one-month follow-up.   
In the traditional dose group, range and VRQoL self-ratings were significantly 
different between baseline and post-intervention.  NHR and CAPE-V breathiness scores 
were significantly different between post-intervention and one-month follow-up.  Range, 
jitter, and CAPE-V overall scores were significantly different between baseline and one-
month follow-up.   
The high dose group demonstrated significantly different NHR and CAPE-V 
overall, strain, and breathiness scores between post-intervention and one-month follow-
up.  Changes in secondary outcome measures are provided in Table 4.7. 
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Table 4.7: Paired Sample T-Tests for Secondary Outcome Measures  
Low Dose Pre-post p-value Post-month p-value Pre-month p-value 
Airflow .453 .430 .766 
Psub .492 .047* .678 
LAR .259 .671 .746 
Range .619 .220 .191 
Jitter .119 .163 .661 
Shimmer  .616 .146 .071 
NHR .510 .321 .285 
CAPE-V Overall .133 .225 .392 
CAPE-V Roughness .314 .251 .879 
CAPE-V Breathiness .062 .347 .110 
CAPE-V Strain .304 .243 .122 
CAPE-V Pitch .347 .345 -- 
CAPE-V Loudness .000* .347 .347 
VRQoL .111 .169 .021* 
Traditional Dose Pre-post p-value Post-month p-value Pre-month p-value 
Airflow .760 .696 1.00 
Psub .506 .212 .634 
LAR .346 .727 .363 
Range .020* .825 .018* 
Jitter .298 .234 .014* 
Shimmer .642 .182 .196 
NHR .811 .044* .061 
CAPE-V Overall .323 .119 .034* 
CAPE-V Roughness .263 .218 .595 
CAPE-V Breathiness .671 .020* .074 
CAPE-V Strain .203 .929 .054 
CAPE-V Pitch .347 .347 .347 
CAPE-V Loudness .347 .347 .347 
VRQoL .043* 1.00 .133 
High Dose Pre-post p-value Post-month p-value Pre-month p-value 
Airflow .639 .297 .368 
Psub .980 .426 .406 
LAR .796 .079 .109 
Range .469 .325 .080 
Jitter .308 .110 .970 
Shimmer .324 .172 .200 
NHR .409 .008* .171 
CAPE-V Overall .161 .004* .104 
CAPE-V Roughness .441 .054 .218 
CAPE-V Breathiness .062 .013* .206 
CAPE-V Strain .569 .024* .106 
CAPE-V Pitch .926 .343 .343 
CAPE-V Loudness .897 .209 .212 
VRQoL .260 .343 .343 
* denotes statistically significant value (p ≤ .05) 
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Summary of outcome measures.  A total of two primary outcome measures and 
14 secondary outcome measures were examined in this study at three time points.   
Overall, the low dose group demonstrated significant change on both primary outcome 
measures and one secondary outcome measure for a total of three significantly changed 
measures between baseline and post-intervention.  Significant change post-intervention to 
one-month follow up occurred for one secondary outcome measure for a total of one 
significant change.  Between baseline and one-month follow-up, one primary outcome 
measure and one secondary outcome measure yielded significant change for a total of 
two significantly changed measures.  The low dose group demonstrated an overall total of 
six improved measures over the course of the study.   
Overall, the traditional dose group demonstrated significant change on both 
primary outcome measures and two secondary outcome measures for a total of four 
significantly changed measures between baseline and post-intervention.  Significant 
change post-intervention to one-month follow up occurred for one primary outcome 
measure, but this value represents a significant decrease (worsening) of that measure.  
Two secondary outcome measures changed significantly in this time period.  A total of 
three significant changes between post-intervention and one-month follow-up were 
found.  Between baseline and one-month follow-up, one primary outcome measure and 
three secondary outcome measures yielded significant change for a total of four 
significantly changed measures.  The traditional dose group demonstrated an overall total 
of eleven significantly changed measures over the course of the study, with ten of those 
representing significant improvement.   
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Overall, the high dose group demonstrated significant change on one primary 
outcome measure for a total of one significantly changed measure between baseline and 
post-intervention.  Significant change post-intervention to one-month follow up occurred 
for one primary outcome measure, but this value represents a significant decrease 
(worsening) of that measure.  Four secondary outcome measures changed significantly in 
this time period.  A total of five significant changes between post-intervention and one-
month follow-up were found.  Between baseline and one-month follow-up, one primary 
outcome measure yielded significant change for a total of one significantly changed 
measure.  The high dose group demonstrated an overall total of seven significantly 
changed measures over the course of the study, with six of those representing significant 
improvement.  The number of statistically significant changes in primary and secondary 
outcome measures for each group can be viewed in Table 4.8. 
The hypothesis that the high dosage group would demonstrate better maintenance 
at follow-up was again disproven when examining maintenance in terms of number of 
significant changes in primary and secondary outcome measures maintained at follow-up.  
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Table 4.8: Number of Significant Changes in Outcome Measures 
 Primary Outcome 
Measures 
(2 possible) 
Secondary 
Outcome Measures 
(14 possible) 
Subtotal 
 
(16 possible) 
Total 
 
(48 possible) 
Low Dose     
Pre-post 2 1 3 6 
6 improved Post-month 0 1 1 
Pre-month 1 1 2 
Traditional Dose     
Pre-post 2 2 4 11 
10 improved Post-month 1+ 2 3 
Pre-month 1 3 4 
High Dose     
Pre-post 1 0 1 7 
6 improved Post-month 1+ 4 5 
Pre-month 1 0 1 
+ denotes a measure that worsened significantly 
Compliance 
 Participant compliance with weekly check-ins was 99% overall.  Only one 
participant failed to attend a check-in on one occasion.  All home practice logs were 
returned with the exception of three logs from one participant.  Compliance was collected 
via home practice logs and was tabulated in terms of number of practice sessions missed.  
The average number of missed practice sessions in the low dose group was nine, and the 
median number of missed practice sessions was one.  Two participants in this group 
missed five or more practice sessions.  The average number of missed practice sessions in 
the traditional dose group was 2.3, and the median number of missed practice sessions 
was zero.  One participant in this group missed five or more practice sessions.  The 
average number of missed practice sessions in the high dose group was 5.8, and the 
median number of missed practice sessions was one.  Two participants in this group 
missed five or more practice sessions.  Compliance with home practice is described 
below in Table 4.9 by dosage group.   
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Table 4.9: Home Exercise Compliance by Dosage Group  
 Mean Practices 
Missed 
Median Practices 
Missed 
Participants 
Missing ≥ 5 
Practices 
Low Dose 9 1 2 
Traditional Dose 2.3 0 1 
High Dose 5.8 1 2 
 
Chapter Summary 
Chapter four served to present the statistical results of the data analysis.  Chapter 
five will discuss the significance of these findings, study limitations, and future directions 
for research. 
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Chapter Five: Discussion 
Review of Purpose 
Although many areas of speech-language pathology lack precision regarding 
optimal dose-response relationships, this issue is especially salient in the area of voice 
due to the potential for toxic effects secondary to vibration over-dose.  In addition, 
optimal dose, or the dose where benefit is maximized without detrimental effects, is 
essential for efficient and effective treatment (Roy 2012).  As Roy mentions, there are 
many aspects of behavioral therapy, and more specifically voice therapy, which make it 
difficult to determine dose-response relationships.   
The primary purpose of this investigation was to examine the effect of varying 
doses of VFE home practice on attainment of pre-established MPT goals in individuals 
with normal voice production.  A secondary purpose of this investigation was to observe 
the presence or absence of observable toxic effects on the vocal folds as a potential result 
of increased VFE home practice.  Finally, this study evaluated a variety of secondary 
outcome measures including self-assessment, auditory-perceptual, aerodynamic, and 
acoustic measures before and after VFE intervention in order to determine whether voice 
assessment parameters change differentially according to dose.  That is, which 
assessment parameters react to low, traditional, and high doses.   
Review of Methodology 
 A total of 28 female participants with normal voice were randomized into one of 
three dosage groups.  All participants attended weekly check-ins and completed home 
practice twice daily for six weeks.  The low dose group did each exercise once, the 
traditional dose group completed each exercise twice, and the high dose group performed 
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each exercise four times.  Therefore, the low dose group practiced a total of 240 minutes 
(one repetition of four minutes, twice daily, for 30 days), the traditional group practiced a 
total of 480 minutes (two repetitions of four minutes, twice daily, for 30 days), and the 
high dose group practiced a total of 960 minutes (four repetitions of four minutes, twice 
daily, for 30 days). 
After six weeks, VFE practice was discontinued, and participants returned one 
month later for follow-up.  Data was collected at baseline, post VFE protocol, and at one-
month follow-up.  An additional laryngeal exam with stroboscopy was performed three 
weeks into the VFE protocol to monitor for observable toxic effects. 
Discussion of Results 	 Group Homogeneity.  A series of one-way ANOVAs demonstrated that the three 
experimental groups were not significantly different at baseline for age, airflow, 
subglottic pressure, laryngeal airway resistance, range, jitter, shimmer, noise-to-
harmonics ratio, acoustic MPT, VFE MPT, CAPE-V scores (overall, roughness, 
breathiness, strain, pitch, loudness), or VRQoL self-ratings.   	 Withdrawal rates.  A total of eight participants withdrew from the study.  Based 
on withdrawal questionnaires, difficulty tolerating the rigid scope for laryngeal 
examination did not appear to be a major factor in the decision to discontinue 
participation.  The most frequently cited reason for withdrawal was excessive time 
commitment, particularly among individuals in the high dose experimental group.  Five 
of the individuals who discontinued the study were from the high dose group, which may 
indicate that doubling the dose of VFEs represents a sub-optimal course of treatment for 
the general population.  If, by increasing dose, compliance diminishes, one might 
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ultimately undermine one of many key components underlying treatment efficacy.  
However, because this study did not examine dose in disordered voice, only speculation 
about VFE dosing in clinical populations can be presented.     	 Goal attainment.  One question this study attempted to answer was whether 
altering the dose of VFE home practice affected pre-established VFE MPT goal 
attainment.  Clinically, individuals who complete VFEs are typically discharged from 
therapy when they reach 80% of their goal.  Therefore, the number of participants in each 
dosage group who reached 80% of their goal was tabulated.  In the low dose group, one 
subject reached 80% of her goal.  In the traditional dose group three subjects reached 
80% of goal.  In the high dose group four subjects reached 80% of goal.  It appears that 
higher doses of VFE home practice may increase the likelihood of reaching MPT goal. 
In previous studies examining traditional doses of VFEs in normal voice, all 
subjects met their goal in approximately two weeks (Stemple et al., 1994).  Failure to 
attain goal in this study may be attributed to exercise technique, to compliance, or to 
other phenomena such as fatigue.  Although compliance was reportedly high, 
misrepresentations in self-reports may obscure non-compliance that may have 
contributed to lack of goal attainment.  It is unclear whether this was the case, 
particularly for the low dose group.  Based on the Stemple et al. (1994) study where all 
participants attained goal in two weeks, it may be reasonable to suggest that, at half the 
dose, participants in the low dose group would have reached goal in less time.  However, 
this was not the case.  By performing exercises less frequently, participants may have 
spent more time in the pre-learning stages than groups who practiced with more 
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repetitions, meaning that consolidation of technique was delayed, thereby resulting in 
poorer goal attainment rates (Spielman et al., 2007).     
A second question this study addressed was whether altering the dose of VFE 
home practice affected time to MPT goal attainment.  In the high dose group, the median 
number of check-ins to goal attainment was five, while the average was 4.74. In the 
traditional dose group, the median number of check-ins to goal attainment was also five, 
but the mean was 5.33.  In the low dose group, where only one subject met 80% of goal, 
attainment was achieved at her one-month follow-up.  The trend suggests that higher 
doses of VFEs result in decreased goal acquisition times.  In the low dose group, it 
appears that VFE MPT improved after discontinuation of exercises.  
Primary outcome measures.  For the primary outcome measure of VFE MPT, 
all three doses of VFEs were sufficient to result in significant changes between baseline 
and post-intervention, and between baseline and follow-up.  The exception was that the 
low dose group did not demonstrate significant change between post-intervention and 
follow-up, indicating that MPT did not decline significantly with home practice 
discontinuation.  Interestingly, the low dose group yielded the lowest percentage (11%) 
of individuals who met 80% of their MPT goal, with only one subject achieving her goal 
after follow-up.  Because this participant did not meet goal during the exercise protocol, 
this suggests that her VFE MPT increased after exercise discontinuation.  For this 
individual, it may be that she improved on this measure without practice, that for some 
reason she performed sub-optimally at post-intervention data collection, or that for some 
reason she performed ideally at follow-up.  As a whole, the low dose group VFE MPT 
decreased slightly between post-intervention and follow-up, but not to a significant 
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degree.  While the low dose group did not improve its VFE MPT as much as the other 
experimental groups, subjects were better able to maintain that improvement.  
 The traditional dose group yielded a higher percentage of individuals who met 
80% of their VFE MPT goal (33%).  The traditional dose group improved more in terms 
of VFE MPT between baseline and post-intervention and between baseline and follow-up 
than the low dose group.  The traditional dose group experienced a significant reduction 
in VFE MPT between post-intervention and one-month follow-up, but maintained 
enough improvement at follow-up to demonstrate better overall outcomes than the low 
dose group.  
 The high dose group yielded the highest percentage of individuals who met 80% 
of their VFE MPT goal (40%).  The high dose group improved more in terms of MPT 
between baseline and post-intervention and between baseline and follow-up than the 
traditional dose group.  Individuals in the high dose group demonstrated a significant 
reduction in MPT between post-intervention and one-month follow-up.  Interestingly, the 
high dose group seemed to yield diminishing returns.  The gap in improvement between 
the high and traditional dose groups was not as great as the gap in improvement between 
the traditional and low dose groups.  This trend was noted despite the fact that doses were 
doubled with each successive group.  In fact, at follow-up, the traditional dose group had 
a higher median percentage point change from baseline than did the high dose group, 
though the average percentage point change was higher in the high dose group.  Because 
medians are less susceptible to being skewed by outliers in the data set, it is reasonable to 
conclude that high and traditional doses of VFE may lead to similar changes in VFE 
MPT between baseline and follow-up. 
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Low doses of VFEs were insufficient to improve vocal function to the same 
extent as higher doses.  Conversely, individuals who completed higher doses of VFEs 
trained higher in that their percentage point change between pre- and post-intervention 
indicated greatest improvement, but lost on average 16 (median of 15) percentage points 
in VFE MPT at one-month follow-up, which represented the largest decline.  By 
comparison, the traditional group lost an average of 11 (median of 9) percentage points 
and the low dose group lost an average of three (median of two) percentage points at 
follow-up.  Thus, improvement maintenance in MPT was similar for the high and 
traditional groups when considering mean and median percentage change. 
 For the primary outcome measure of acoustic MPT, only the low and traditional 
dose groups significantly improved from pre- to post-intervention.  Acoustic MPT refers 
to MPT taken on the vowel /a/ without use of a semi-occluded vocal tract posture.  No 
other time points demonstrated significant change for any of the three dosage groups.  
The high dose group, despite improvement in MPT, did not demonstrate significant 
difference in acoustic MPT.  The traditional group demonstrated better outcomes at 
follow-up in acoustic MPT as compared to any other group, but change in acoustic MPT 
from baseline to follow-up was not statistically significant.   
Toxicity.  In this study, no obvious toxic effects to the vocal fold mucosa were 
observed in any of the intervention groups as visually and subjectively assessed using 
stroboscopy and through the use of perceptual rating scales.  Toxicity was monitored via 
weekly completion of the VRQoL by each participant and by stroboscopic evaluation 
after three weeks and six weeks of exercise completion.  One participant in the high dose 
group discontinued the study in the first week, complaining of throat pain and fatigue.  
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She was interviewed and told the researcher that she was involved in a choral group and 
that the exercises in addition to her rehearsal schedule likely led to her noticeable 
discomfort.  She refused a follow-up laryngeal examination.  No other reports of vocal 
fatigue, pain, or soreness were made throughout the course of the study for any other 
participant.  It can also be noted from the data that for the individuals who reached goal 
prior to finishing the six-week protocol, continuing practice past the point of goal 
attainment did not produce observable toxic effects.  All participants continued daily 
practice for six weeks, yet no observable detrimental effects were observed or reported.  
Based on the results of this study, high doses of VFEs consisting of four repetitions of 
each exercise twice daily for six weeks were not found to result in detrimental effects in 
individuals with normal voice, using the objective and subjective measures previously 
indicated.  
Secondary outcome measures.  Another question this study attempted to address 
was which vocal assessment parameters changed with low doses, traditional doses, and 
high doses of VFEs.  Because the sample in this study consisted of individuals with 
normal voice, many of the secondary outcome measures demonstrated few statistically 
significant differences.  Of these, low doses produced statistically significant (1) 
improvement in CAPE-V loudness from baseline to post-intervention, (2) decreased 
subglottic pressure differences from post-treatment to one-month follow-up, and (3) 
improved VRQoL self-ratings (significantly decreased) from baseline to one-month 
follow-up. 
Traditional doses produced statistically significant (1) improvement in pitch range 
between baseline and post-intervention as well as (2) between baseline and one-month 
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follow-up.  Pitch range did not significantly differ as a result of discontinuing daily 
exercise, suggesting that this variable is more readily maintained with traditional doses of 
VFEs.  (3) Jitter significantly decreased (improvement) between baseline and one-month 
follow-up.  (4) NHR significantly decreased (improvement) between post-intervention 
data collection and one-month follow-up.  The results for jitter and NHR indicate that 
these variables may continue to improve after discontinuation of practiced exercises.  (5) 
Overall CAPE-V scores improved significantly from baseline to one-month follow-up, 
with (6) breathiness significantly decreasing (improved) between post-intervention and 
one-month follow-up, and (7) VRQoL decreasing (improved) significantly from baseline 
to post-intervention.    
High doses produced statistically significant (1) decreases (improvements) in 
NHR, (2) overall CAPE-V score, (3) breathiness, and (4) strain between post-intervention 
and follow-up.  No other statistically significant changes were made pre-post intervention 
or baseline to one-month follow-up for secondary outcome measures in this group.     
Summary of outcome measures.  The low dose group improved on a total of six 
outcome measures over the course of this study, yet only two measures demonstrated 
longer-term improvement at one-month follow-up.  The traditional dose group improved 
on a total of ten outcome measures over the course of this study, with only four measures 
demonstrating continued improvement at one-month follow-up.  The high dose group 
improved on a total of six outcome measures over the course of this study, but only one 
measure continued to demonstrate improvement at one-month follow-up.  Summarizing 
results using tabulation of total number of improved outcome measures provides some 
important insights: (1) low and high dose groups demonstrated the same number of 
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improved measures, (2) the low dose group demonstrated more maintained improvements 
at follow-up than the high dose group, (3) the traditional dose group demonstrated highest 
number of improved and maintained measures.  While the high dose group may have 
demonstrated greatest improvement on some outcome measures, the number and 
maintenance of improved measures were not superior to other groups. 
Interestingly, the outcome measures that had significantly improved at one-month 
follow-up were not always the same outcome measures that improved from baseline to 
post-intervention.  This is particularly true of the secondary outcome measures, indicating 
a likely interaction between intervention and secondary outcome measures in normal 
voice.  In summary, low doses of VFEs may be sufficient to improve some voice 
outcome measures, but these gains may be diminished in comparison to the improvement 
that higher doses yield.  In normal voices, higher doses may not intrinsically mean better 
outcomes or better maintenance.  In this study, traditional doses of VFEs appear to have 
resulted in the best overall maintenance of the practiced tasks. 
Compliance.  Compliance is the state of an individual adhering to a pattern of 
treatment.  While compliance exists separately from dose, it may have a substantial effect 
on overall therapeutic outcomes because it represents accumulation of an active 
ingredient over time.  Because compliance, or non-compliance, may affect treatment 
outcomes, it is a vital consideration in behavioral intervention.     
In terms of compliance, high doses of VFEs increased the withdrawal rate of 
participants to 50%.  Given the importance of compliance in voice therapy, increasing 
dose may undermine one of many key components of the program and reduce its 
effectiveness.  Interestingly, low doses also elicited poorer compliance.  Out of the three 
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groups, the traditional dose group exhibited superior compliance in every form: (1) mean 
number of missed practice sessions, (2) median number of missed practice sessions, and 
(3) number of participants who missed five or more practice sessions.  This may because 
fewer repetitions during practice led to longer amounts of time spent in the pre-learning 
stage, where technique is not yet consolidated.  This may have influenced the motivation 
of individuals in the low dose group, who may have felt less confident in their ability to 
perform the exercises.  It is hypothesized that compliance may influence over all 
treatment effect and may represent a leading factor in determining outcomes both in basic 
and in clinical research. 
A study by Wenke et. al (2014) described characteristics of individuals who were 
more likely to attend therapy.  Candidates likely to complete voice therapy were young, 
employed females with fewer laryngeal diagnoses and medical problems, less severe 
voice disorders, and lower Voice Handicap Index scores at baseline.  While the 
participants in this study were similar to the described population, they were vocally 
normal and therefore did not have any type of disorder.  This may or may not have 
affected their motivation to be compliant with the intervention protocol.  More broadly, 
this may be an intrinsic flaw in the study of dose in normal subjects.    
Limitations and Delimitations 
 The present study contains certain limitations, one of which is that compliance 
with home practice was self-reported and could not be verified by the researcher.  Non-
compliance with home practice could significantly alter the individual’s treatment 
outcomes, particularly at the post-exercise data collection point.  Certain aspects of this 
study’s methodology were included specifically to address this limitation.  First, 
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compliance was stressed to all participants, who were provided with face videos to guide 
and facilitate home practice.  Second, participants were reminded to practice twice daily 
via email.  Third, home practice logs were kept and returned weekly.   
 A second limitation is that research assistants, rather than clinicians specialized in 
voice, provided guidance for weekly check-ins.  Although this study addressed VFE use 
in individuals with normal voice, research assistants lack the expertise that an 
experienced voice clinician would have.  Less effective or efficient feedback and 
instruction provided by research assistants may have diminished the efficacy of VFEs and 
may also have reduced participant compliance.  This limitation was addressed by several 
aspects of the study’s design.  First, research assistants received training from a speech-
language pathologist and expert in voice.  Technique was then reviewed individually on 
two separate occasions.  Second, upon initial teaching of VFEs to each participant, voice 
clinicians with extensive experience using and teaching VFEs confirmed technique with 
each subject and established VFE MPT baselines.  Third, 20% of all weekly check-ins 
were supervised by experienced voice clinicians, and an additional 20% were monitored 
by a second year graduate student with experience teaching and using VFEs.  Finally, it is 
important to point out that one attractive quality of the VFE program is that it is fairly 
simple to teach and practice (Stemple, Glaze, & Gerdeman, 2000).     
 A number of delimitations were also present in this study.  First, this study 
addressed VFE dosage in individuals with normal voice, and therefore conclusions about 
pathological populations cannot be drawn.  Second, the small sample size used in this 
study only permits this data to be used for preliminary purposes.  Third, only three 
distinct dosages were examined during this study.  Therefore, conclusions about even 
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higher dosages cannot be drawn.  As Baker (2012) points out, when a more intense 
treatment or a higher dosage does not lead to increased gains, one is left to wonder if one 
has proof that there is no additional benefit or if the intensity studied simply was not 
intense enough.  Conclusions about the effects of adjusting intensity or dosage in other 
ways (number of sessions per week, overall length of intervention, etc.) cannot be made.  
Fourth, there was no attrition component to this study.  Given that data collection took 
place during the fall, upper respiratory infections and allergies could not be avoided.  
Fifth, although all participants were asked to agree not to engage in vocally harmful 
behaviors, vocal hygiene was not tracked or reported.  Finally, no tapering schedule was 
used, as recommended following VFE protocols in clinical settings.  Typically, after 
reaching VFE MPT goal, the clinician guides the individual in gradually reducing their 
practice intensity of VFEs over a number of weeks, with the criterion of maintaining and 
sustaining 85% of their original MPT goal.  In this study, exercises were discontinued 
completely after six weeks.  One-month follow-up data in this study should be interpreted 
with this in mind, as absence of tapering programs diminishes maintenance.        
Implications for Future Research 
 Due to the aforementioned limitations and delimitations, further research is 
necessary to determine optimal dose-response relationships for VFEs in normal voice.  
This would include research using larger sample sizes and a greater variety of dosage 
groups.  If possible, alternate means of compliance tracking, for example a web-based 
application that would provide instructions, obtain MPT, and send reports to researchers, 
may be used.  Previous studies have demonstrated that groups of participants in 
compliance-monitored VFE groups improved significantly more on MPT in comparison 
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to unmonitored groups.  Monitored groups were asked to submit audio or video recording 
of exercises, which presumably increases accountability (Ellis et al., 2011).   
 Future research should also include additional data, for example confidence self-
ratings from clinicians, research assistants, and study participants regarding VFE 
technique.  Additionally, clinicians could rate the accuracy of each subject’s technique 
when performing exercises.  This information could be vital in interpreting outcomes, as 
better technique may correlate with compliance, goal attainment, and time to goal 
attainment, among other variables.  Additionally, superior technique implies a higher 
dose if technique is an essential active ingredient of VFEs.        
The scarcity of research on dose-response relationships in behavioral therapy, 
particularly in voice therapy, is apparent after an extensive literature review.  More 
research investigating the effects of modifying VFE dosage on outcome measures is 
necessary for establishing more efficient treatment models.  This may include a greater 
variety of dosage groups or alternate methods of increasing and decreasing dose or 
intensity.  Optimal dose-response relationships in normal voice must be investigated prior 
to exploration in clinical populations.  Data on clinical populations would be useful in 
determining the window for greatest improvement in the pathological voice, thereby 
improving efficiency of treatment and accuracy of prognoses.  This is especially 
important in identifying potential thresholds for vibration over-dose or toxicity levels.  
Significance of the study 
This is a pilot dosage study.  It is one of the only studies to examine the effects of 
varying dose in voice intervention and the first one to systematically examine varying 
exposure to VFEs.  Studying dosage in normal voice is an important first step to research 
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that examines dosage in clinical populations and serves as a contribution toward defining 
intervention that is not only effective but also more efficient.  Efficiency of treatment is 
essential to sparing much in the way of time, resources, effort, and money on the part of 
the healthcare organization, client, clinician, and third party payer. 
Contribution to the literature on dosage.  Increased dosages of VFEs have not 
been previously examined, making this study the first to do so.  However, there are a 
number of studies presented in the literature review in chapter two that have examined 
reduced exposures to VFEs.  These studies suggest that lower exposures of VFEs may 
improve the normal voice, but to a lesser degree.  Ellis and Beltyukova (2011) found that 
in two groups of adult women with normal voice who performed VFEs, both groups 
improved significantly but the group that was monitored for compliance improved 
significantly more. 
In disordered voice, Pasa et al. (2007) compared groups of teachers with self-
reported voice problems who completed either VFEs or vocal hygiene (VH).  The 
treatment delivery model consisted of a group format with reduced clinician contact time.  
The VH group improved more on measures of voice characteristics and knowledge of 
vocal health.  Berg et al. (2008) examined VRQoL scores in individuals with age-related 
dysphonia after completion of VFEs.  As part of the study, they demonstrated that 
subjects who were described as “adherent” demonstrated better improvement in 
comparison to those who were “partially adherent,” though definitions for these terms 
were not provided and compliance did not appear to be explicitly tracked.  Nguyen and 
Kenny (2009) compared two groups of primary teachers with muscles tension dysphonia.  
One group performed a full VFE protocol, while the other completed a partial protocol 
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consisting only of the first exercise.  The full protocol group demonstrated better 
outcomes on a variety of outcome measures.   
These studies all provide examples of outcomes secondary to reduction of 
traditional VFE exposure.  Previous literature and the present study support the idea that 
reductions in VFE exposure result in suboptimal outcomes in normal voice.  However, 
specific changes in dosage have never been systematically examined, and dosage and 
compliance should not be confounded.  While dosage, compliance, and even dose are 
intrinsically related, they must also be carefully separated.   
In pharmacology, dose is an amount of an agent given at an instant in time.  For 
VFEs, dose cannot be determined because the agent (active ingredient) remains 
unknown.  Somewhat related to dose is dosage, which refers to a pattern of delivery.  In 
this study, dosage was the independent variable that was systematically manipulated in 
order to develop a dosage-response curve.  Dosage-response curves describe how 
frequently a given quantity should be administered in order to yield therapeutic effect.  
However, therapeutic effects are additive in nature and intrinsically affected by 
compliance.  That is, the state of an individual adhering to a pattern of treatment, which is 
complex in nature.  While compliance does not directly affect dose or dosage, it has an 
important impact on therapeutic effect and cannot be discounted in any intervention, 
particularly in behavioral interventions.  
Dosage as integral to principles of sensory motor learning.  In behavioral 
interventions such as VFEs, dosage takes on another facet, which cannot be accounted for 
in pharmacology.  The important difference is that behavioral interventions may require 
learning of a motor task.  Learning is a process of acquiring a skilled action that results 
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from experience or practice and produces relatively permanent changes in behavior 
(Shumway-Cook & Woollacott, 2012).  Research indicates that neural plasticity is the 
basis for motor learning, and that there are specific strategies for enhancing neural 
plasticity.  These strategies are commonly referred to as the principles of sensory motor 
learning, which dictate key components vital to learning skilled movements.  Some of the 
most salient principles will be discussed in terms of skill acquisition for VFEs.     
Specificity.  Specific forms of neural plasticity depend on specific experiences.  
Neural plasticity is facilitated during practice that closely approximates the skill to be 
learned (Kleim & Jones, 2008).  In this study, participants in the high dosage group were 
asked to perform more repetitions of exercises prior to skill acquisition.  This may have 
diminished the advantage of increased repetition, particularly during early practice, which 
could partially explain why participants in the high dosage group attained goal only 
slightly more quickly than subjects in the traditional group.  More broadly, demanding 
higher repetitions prior to skill acquisition may have led to frustration or reduced 
compliance, and may have increased risk of toxic effects on the vocal mechanism. 
Intensity.  Intense practice is important in maximizing plasticity.  Intensity can be 
increased by demanding greater effort, accuracy, force, repetition, or frequency (Kleim & 
Jones, 2008).   In this study, intensity was modified by altering the number of repetitions 
required from each experimental group.  Because repetitions were performed 
successively, without rest, it is likely that participants in the high dosage group expelled 
more effort as they became fatigued.  Intensity is a key principle for establishing a 
dosage-response curve for VFEs because intensity of intervention affects skill 
acquisition, and because changes in dosage may also modify intensity. 
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Repetition.  Lasting neural changes require repetition of a newly learned behavior 
(Kleim & Jones, 2008).  In this study, dosage was manipulated by altering the number of 
repetitions required for each group.  Ultimately, the high dosage group demonstrated the 
greatest improvement in semi-occluded MPT, which may indicate that higher repetitions 
were advantageous for skill acquisition.  Repetition is a key principal for establishing a 
dosage-response curve for VFEs because repetition affects skill acquisition, and because 
changes in dosage may be made by altering repetition.   
Clinical implications.  While this study examined normal voice, pilot data may 
offer limited clinical perspective as well.  Clinically, speech-language pathologists 
consider a number of elements when designing treatment plans that determine how time 
is structured within sessions and during independent practice.  Decisions regarding 
treatment are partly based on clinical intuition regarding prognosis, rate of recovery, and 
extent of improvement required for realization of individual needs.  Thus, in instructing 
clients on home practice schedules, it is important to weigh client-spent effort and time 
against expected benefits of (extended) practice.     
High doses of VFEs may be feasible for select individuals, particularly for those 
who are highly motivated or who are vocally athletic.  It may be feasible to increase 
dosage after establishing acceptable technique at the traditional dose.  Altering dosage 
after skill acquisition provides the client with ample opportunity to stabilize proper 
technique and avoids frustration and burdensome time requirements while learning the 
task.  Increasing dosage after skill acquisition also better satisfies the principle of 
specificity, while incorporating increased repetition and intensity.  Another advantage is 
that, with good technique, concern for toxicity diminishes.  For vocal athletes (e.g. 
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trained singers), higher doses of VFEs might be appropriate when training for specific 
vocal events or performances.      
It is important to mention that dose may not be the most critical factor 
determining goal attainment or time to goal attainment.  As Roy (2012) mentions, 
efficacy of treatment is dependent on dose, intensity, active therapeutic ingredients, and a 
host of other variables existing within and without the client.  Dose may, however, be a 
major factor in determining overall improvement, even when effects are not maintained.   
Clinically, tapering schedules are used to curb post-treatment decline in MPT by 
pinpointing the minimal practice required to maintain vocal efficiency.  This study did 
not implement a tapering program, and therefore the data on maintenance must be 
interpreted with such a design in mind.  In this study, successively higher doses of VFEs 
led to steeper declines in MPT after discontinuation of exercise.  This study provides a 
vivid example of how quickly vocal improvements may dissipate with immediate 
cessation of exercise.        
Clinically, low doses of VFEs may be insufficient to improve the voice, and 
higher dose may not result in better outcomes or maintenance.  However, more research 
is needed to determine the effects of varying doses of VFE home practice in the 
pathological voice. 
Conclusions 
No toxic effects in vocal fold condition or phonation were observed or measured 
throughout this study of normal voice involving a six-week regimen of VFEs practiced 
up to four times each, twice daily.  Toxic effects of intense voice treatment have not yet 
been defined, which is in keeping with previous literature. 
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For physiologic goal, varying the dose of home practice alters MPT attainment in 
normal voice.  Low exposures to VFEs may prevent individuals from reaching MPT goal.  
High doses may improve time to goal attainment and likelihood of goal attainment.  The 
effects observed in VFE MPT may not transfer to acoustic MPT.  Low and traditional 
dose groups demonstrated similar improvement in acoustic MPT, while the high dose 
group did not demonstrate significant change in this measure. 
For primary and secondary outcome measures, low and high doses resulted in the 
same number of significant improvements.  Traditional doses demonstrated the greatest 
number of statistically significant changes.  
Maintenance can be viewed in terms of decrease in VFE MPT after completion of 
the intervention protocol.  Under the lens of decreased MPT, the low dose group 
displayed the best maintenance.  Alternatively, maintenance may be defined in terms of 
the number of significantly improved outcome measures at follow-up.  In the case of 
quantity of improved outcome measures, the traditional dose group demonstrated the best 
maintenance.  This may be related to the fact that this group also exhibited highest 
compliance, which may have affected overall treatment outcomes.   
In summary, low doses of VFEs may improve normal voice, though 
insufficiently.  High doses may not produce gains beyond traditional doses, particularly at 
follow-up.  Therefore, blanket alterations of dosage are not likely to be feasible.  As in 
pharmacology, where dose is adjusted according to variables such as age, weight, and 
gender, it is feasible that dosing in voice must also be individualized to some extent.  The 
variables determining appropriate dosing cannot be enumerated with certainty, but level 
of motivation, baseline function, and individual goals are likely to be salient.  
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Chapter Summary 
 Chapter five served to discus the results of this study, their significance, and their 
clinical implications.  Limitations and delimitations, as well as directions for future 
research were also outlined in this chapter.   
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Appendix A: Recruitment Flyer 
University of Kentucky Research 
 
 
Volunteers Needed for a Study of Voice Production 
 
 
Researchers at the University of Kentucky, College of Health Sciences need participants 
as a part of a study they are conducting. Testing involves detailed throat examination and 
voice quality measures. You would need to come in 8 times for about 1 hour.  
 
 
You may be able to participate if you: 
 
! Are between 18-25 years old 
! Are female 
! Are a non-smoker 
! Have not had a year or more of classical vocal training 
! Do not have a history of uncontrolled asthma 
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Appendix B: Consent Form 
Combined Consent and Authorization to Participate in a Research Study  
VOCAL FUNCTION EXERCISES FOR NORMAL VOICE: THE EFFECTS OF 
VARYING DOSAGE  
WHY ARE YOU BEING INVITED TO TAKE PART IN THIS RESEARCH? 
You are being invited to take part in a research study that will examine the effects of 
varying dosage of Vocal Function Exercises on the maximum phonation time in 
individuals with normal voice. You are being invited to take part in this research study as 
a volunteer in one of three groups, and your group assignment will be determined 
randomly.  If you volunteer to take part in this study, you will be one of about 30 people 
to do so.       
 
WHO IS DOING THE STUDY? 
 
The person in charge of this study is Maria Bane of the University of Kentucky, 
Department of Communication Sciences and Disorders.  Maria Bane is a graduate 
student.  She is being guided in this research by faculty advisor Joseph Stemple, Ph.D., 
CCC-SLP.  There may be other people on the research team assisting at different times 
during the study.  
 
WHAT IS THE PURPOSE OF THIS STUDY? 
 
With this study, we hope to learn more about how varying the dose of Vocal Function 
Exercises affects time to maximum phonation goal attainment in the normal voice. 
 
ARE THERE REASONS WHY YOU SHOULD NOT TAKE PART IN THIS 
STUDY? 
You should not take part in this study if you are younger than 18 or older than 25 years of 
age.  If you have a history of uncontrolled asthma, are a smoker, or have a year or more 
of classical voice training, you should not take part in this study.   
WHERE IS THE STUDY GOING TO TAKE PLACE AND HOW LONG WILL IT 
LAST?  
The research procedures will be conducted at the University of Kentucky Voice and 
Swallow Clinic in room 116F and 106C of the Charles T. Wethington building and in the 
University of Kentucky Academic Clinic in room 110 of the Charles T. Wethington 
building.  You will be asked to come in for treatment or assessment a total of 7 times, and 
each visit will take on average one hour.  These sessions will take place over a 4-month 
period.  In addition, you will be asked to do exercises at home in the morning and in the 
evening, and this will take you about 10 minutes each time.       
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WHAT WILL YOU BE ASKED TO DO? 
At your arrival, we will assess your voice at its current (baseline) functioning, which will 
include: 
• Voice self-assessment: You will be asked to fill out a questionnaire on the quality 
of your voice. 
• Visual imaging of the appearance and movements of vocal/laryngeal structures: 
An endoscope attached to a digital camera and recorder will be placed into your 
mouth and a recording will be made of the vocal folds as they produce voice.   
• Audio-visual recordings of your voice: These measures will be obtained while 
you voice or breathe into a microphone and an airflow mask.  Researchers will 
then measure the air pressure and airflow out of your mouth that you use during 
voice production.  Voice samples and airflow measures may be taken several 
times to ensure consistency.   
• Auditory-perceptual rating: A speech-language pathologist who specializes in 
voice will listen to your speaking voice and rate its quality and characteristics.  
Clinical visits: 
Date of 
Visit 
Purpose Procedures 
9/25/15 Baseline & Session 1 Full voice assessment; learn 
Vocal Function Exercises 
(VFEs) 
10/2/15 Session 2 VFEs; complete 
questionnaire  
10/9/15 Session 3  VFEs; complete 
questionnaire 
10/16/15 Session 4 & Midpoint Data Collection VFEs; complete 
questionnaire; visual 
imaging of vocal folds 
10/23/15 Session 5 VFEs; complete 
questionnaire 
10/30/15 Session 6 VFEs; complete 
questionnaire 
11/6/15 Data Collection Full voice assessment 
12/4/15 Maintenance Data Collection (1-month 
follow-up) 
Full voice assessment 
At home exercises: You will be assigned to one of three groups randomly (by chance).  
All three groups will be asked to do the same exercises, however the number of times you 
perform the exercises will vary.  The exercises will be performed at each session and also 
independently at home with the guidance of a smartphone application.  See the group 
descriptions as well as the list of exercises below: 
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Group Frequency of Vocal Function Exercises (VFEs) 
Low dose group One time each, twice daily 
Traditional dose group Two times each, twice daily 
High dose group Four times each, twice daily 
 
Exercise Description 
1 Warm up exercise- sustain vowel “ee” as long as possible 
2 Stretching exercise- glide upward from lowest to highest note on the word 
“knoll” 
3 Contracting exercise- glide downward from highest to lowest note on the 
word “knoll” 
4 Low impact adductory power exercise- sustain the musical notes C-D-E-
F-G for as long as possible on “oll” 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? 
During the assessment and data collection, the scope will be passed into your mouth to 
view your vocal folds.  This may be momentarily uncomfortable.  With the mouth scope, 
there is a chance of gagging which can be uncomfortable.  If your vocal folds show any 
abnormality, you will be referred to an Ear, Nose and Throat physician in the Kentucky 
Clinic or another ENT doctor of their choice.  There are no known risks associated with 
audio recording or collecting air coming out of your mouth during speech.  There is 
always a chance that any medical treatment can negatively affect you, and the 
investigational treatment in this study is no different.  Possible minor reversible side 
effects of Vocal Function Exercises include edema to the vocal fold mucosa and 
muscular soreness.  This may result in temporary decrease in vocal quality, for example 
hoarseness.  In addition to the risks listed above, you may experience a previously 
unknown risk or side effect. 
WILL YOU BENEFIT FROM TAKING PART IN THIS STUDY? 
There is no guarantee that you will get any benefit from taking part in this study.  
However, your willingness to participate may, in the future, help speech-language 
pathologists more efficiently treat voice disorders.  
DO YOU HAVE TO TAKE PART IN THE STUDY? 
If you decide to take part in the study, it should be because you really want to volunteer.  
You will not lose any benefits or rights you would normally have if you choose not to 
volunteer.  You can stop at any time during the study and still keep the benefits and rights 
you had before volunteering.  As a student, if you decide not to take part in this study, 
your choice will have no effect on your academic status or grade in any of your classes. 
 	 69	
IF YOU DON’T WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER 
CHOICES? 
If you do not want to take part in the study, there are no other choices except not to take 
part in the study. 
WHAT WILL IT COST YOU TO PARTICIPATE? 
There is no cost to you or your insurance company for you to participate in this study 
since these procedures are part of research at the University of Kentucky.  
 
WHO WILL SEE THE INFORMATION THAT YOU GIVE? 
 
We will keep private all research records that identify you to the extent allowed by law.  
Your information will be combined with information from other people taking part in the 
study.  When we write about the study to share it with other researchers, we will write 
about the combined information we have gathered.  You will not be personally identified 
in these written materials.  We may publish the results of this study; however, we will 
keep your name and other identifying information private.  We will make every effort to 
prevent anyone who is not on the research team from knowing that you gave us 
information, or what that information is.  Your personal information will be accessible 
only to research personnel.  Officials at the University of Kentucky may look at or copy 
pertinent portions of records that identify you.   
CAN YOUR TAKING PART IN THE STUDY END EARLY? 
If you decide to take part in the study you still have the right to decide at any time that 
you no longer want to continue. You will not be treated differently if you decide to stop 
taking part in the study.  Any identifiable research information resulting from your 
participation in this research study prior to the date that you formally withdraw your 
consent may continue to be used and disclosed by the investigators for the purpose 
described in the previous section. 
ARE YOU PARTICIPATING OR CAN YOU PARTICIPATE IN ANOTHER 
RESEARCH STUDY AT THE SAME TIME AS PARTICIPATING IN THIS 
ONE? 
You may take part in this study if you are currently involved in another research study.  It 
is important to let the investigator/your doctor know if you are in another research study.  
You should also discuss with the investigator before you agree to participate in another 
research study while you are enrolled in this study. 
WHAT HAPPENS IF YOU GET HURT OR SICK DURING THE STUDY? 
If you believe that you have gotten hurt or sick as a result of participation in this study, 
you should contact Maria Bane at maria.bane@uky.edu and Dr. Joseph Stemple at 
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jcstem2@uky.edu.  In case an abnormality of your voice is found during the assessment 
you will be referred to the UK Voice and Swallow Clinic.  Should you choose to proceed 
with treatment, you and/or your insurance company will be responsible for the costs of all 
care and treatment.  
 
It is important for you to understand that the University of Kentucky does not have funds 
set aside to pay for the cost of any care or treatment that might be necessary because you 
get hurt or sick while taking part in this study.  Also, the University of Kentucky will not 
pay for any wages you may lose if you are negatively affected by this study.  The medical 
costs related to your care and treatment because of research related discomfort will be 
your responsibility.  Depending on your insurance, you may be paid by Medicare or 
Medicaid if you are covered (if you have any questions regarding Medicare/Medicaid 
coverage you should contact Medicare by calling 1-800-Medicare (1-800-633-4227) or 
Medicaid at 1-800-635-2570.  A co-payment/deductible from you may be required by 
your insurer or Medicare/Medicaid even if your insurer or Medicare/Medicaid has agreed 
to pay the costs).  The amount of this co-payment/deductible may be substantial.   
 
You do not give up your legal rights by signing this form. 
 
WILL YOU RECEIVE ANY REWARDS FOR TAKING PART IN THIS STUDY? 
 
You will not receive any rewards or payment for taking part in the study. 
 
WHAT IF YOU HAVE QUESTIONS, SUGGESTIONS, CONCERNS, OR 
COMPLAINTS? 
 
Before you decide whether to accept this invitation to take part in the study, please ask 
any questions that might come to mind now.  Later, if you have questions, suggestions, 
concerns, or complaints about the study, you can contact the investigator, Maria Bane, at 
859-421-1337.  If you have any questions about your rights as a volunteer in this 
research, contact the staff in the Office of Research Integrity at the University of 
Kentucky between the business hours of 8am and 5pm EST, Mon-Fri at 859-257-9428 or 
toll free at 1-866-400-9428. We will give you a signed copy of this consent form to take 
with you. 
 
WHAT IF NEW INFORMATION IS LEARNED DURING THE STUDY THAT 
MIGHT AFFECT YOUR DECISION TO PARTICIPATE? 
 
If the researcher learns of new information in regards to this study, and it might change 
your willingness to stay in this study, the information will be provided to you.  You may 
be asked to sign a new informed consent form if the information is provided to you after 
you have joined the study.  
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POTENTIAL FUTURE USE   
 
Contacting Research Subjects for Future Studies: Do you give your permission to be 
contacted in the future by Maria Bane  regarding your willingness to participate in future 
research studies about how to prevent, detect, or treat voice disorders?   
 
o   Yes  o   No  _________Initials 
WHAT ELSE DO YOU NEED TO KNOW? 
There is a possibility that the data collected from you may be shared with other 
investigators in the future.  If that is the case data will not contain information that can 
identify you unless you give your consent/authorization or the UK Institutional Review 
Board (IRB) approves the research.  The IRB is a committee that reviews ethical issues, 
according to federal, state and local regulations on research with human subjects, to make 
sure the study complies with these before approval of a research study is issued. 
We have no financial disclosures to include for the present study. 
 
AUTHORIZATION TO USE OR DISCLOSE YOUR IDENTIFIABLE HEALTH 
INFORMATION  
 
The privacy law, HIPAA (Health Insurance Portability and Accountability Act), requires 
researchers to protect your health information.  The following sections of the form 
describe how researchers may use your health information.   
 
Your health information that may be accessed, used and/or released includes: 
 
• Your name, date of birth, and telephone number 
• Visual images from stroboscopic exams  
• Averages, time to goal attainment, and data related to Vocal Function 
Exercise performance at home and during sessions  
• Audio-visual recordings of your voice 
• Questionnaires and auditory-perceptual ratings regarding your voice  
 
The Researchers may use and share your health information with: 
 
• The University of Kentucky’s Institutional Review Board/Office of Research 
Integrity. 
• Your information will be shared with only the research personnel participating 
in the present study.  A list of the personnel is listed below: 
o Maria Bane, B.H.S., graduate student, Principal Investigator 
o Joseph Stemple, Ph.D, CCC-SLP, Faculty Advisor 
o Vrushali Angadi, M.S., Co-investigator 
 
The researchers agree to only share your health information with the people listed in this 
document.   
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Should your health information be released to anyone that is not regulated by the privacy 
law, your health information may be shared with others without your permission; 
however, the use of your health information would still be regulated by applicable federal 
and state laws.   
Electronic data will be deleted according to University guidelines. 
Dates for data collection are from September 25th 2015 to December 4th 2015. 
You will not be allowed to participate in the research study if you do not sign this form.   
If you decide not to sign the form, it will not affect your: 
• Current or future healthcare at the University of Kentucky 
• Current or future payments to the University of Kentucky   
• Ability to enroll in any health plans (if applicable) 
• Eligibility for benefits (if applicable) 
 
After signing the form, you can change your mind and NOT let the researcher(s) 
collect or release your health information (revoke the Authorization). If you revoke 
the authorization: 
 
• You will send a written letter to: Maria Bane, B.H.S. at 900 South Limestone, 
Suite 120, Lexington, KY 40503 to inform her of your decision. 
• Researchers may use and release your health information already collected for 
this research study. 
• Your protected health information may still be used and released should you have 
a bad reaction (adverse event). 
The use and sharing of your information has no time limit.  
 
If you have not already received a copy of the Privacy Notice, you may request one.  
If you have any questions about your privacy rights, you should contact the 
University of Kentucky’s Privacy Officer between the business hours of 8am and 
5pm EST, Mon-Fri at: (859) 323-1184. 
You are the subject or are authorized to act on behalf of the subject.  You have read 
this information, and you will receive a copy of this form after it is signed. 
 
_________________________________                         __________________ 
Signature of research subject              Date 
     
____________________________________       
Name of [authorized] person obtaining informed    
consent/HIPAA authorization          
 
_________________________________________   __________________ 
Signature of Principal Investigator or Sub/Co-Investigator   Date 
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Appendix C:  Inclusion/ Exclusion Criteria Checklist 
 
 
High, Traditional, & Low Exposure Groups 
 
Inclusion criteria 
 
Response to each criterion should be ‘yes’ for subject to 
qualify 
Individual >18 and <26 
years of age 
 
Hearing within functional 
limits 
 
Agree to avoid abusive 
vocal behaviors during 
study participation 
 
Non-smoker  
 
 
 
 
Exclusion criteria 
 
Response to each criterion should be ‘no’ for subject to 
qualify 
Smoker  
Trained singer (≥1 year of 
classical voice training) 
 
Hearing level not 
functional for instruction 
 
History of uncontrolled 
asthma 
 
Vocal fold pathology 
identified by laryngeal 
exam 
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Appendix D: Study Checklist 
 
DATE: 
 
Please circle ‘yes’ for each item that has been completed                                                                                               
 
Subject #: High/ Traditional/ Low/ (circle 1)    ______ (number)      
*(Subjects will be coded as High/ Traditional/ Low 01, 02 etc.) 
 
Informed consent:   Yes / No 
 
VRQoL:  Yes / No   Score (10-50): _____           Overall Voice Quality: _____ 
 
CAPE-V:    Yes / No 
Overall quality (> 29 disqualifies)  
 
 
Acoustics: Yes/No 
Maximum phonation time  
Frequency range  
Noise to harmonics ratio  
Shimmer dB  
Jitter percent  
 
 
Aerodynamics: Yes/No 
Vital capacity  
Airflow rate  
Mean peak air pressure  
Laryngeal airway resistance  
 
 
Strobe: Yes/No  Exam: Rigid 
0= Normal / 1= Abnormal 
 
If abnormal: (select one) 
Glottic closure  
Mucosal wave  
Supraglottic hyperfunction  
Phase symmetry  
  
If other, please identify:______________________________ 
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Appendix E: Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V) 
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Appendix F: Otolaryngology Associates, P.C. 
Voice Related Quality of Life (V-RQOL) 
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Appendix G: Vocal Function Exercise Program 
 
The following four exercises are performed twice daily (morning and evening) the 
prescribed number of times (according to dose) for 6 weeks. 
 
Exercise 1: Warm up exercise- sustain vowel /i/ as long as possible 
• Females on musical not F above middle C 
• Extreme forward focus “almost but not quite nasal” 
Goal- sustained /i/ equal to vital capacity/ 80 mL/s (physiologic goal). 
 
Exercise 2: Stretching exercise- glide upward from lowest to highest note on the word 
“knoll” 
• Extreme forward placement, open pharynx, and sympathetic lip vibration 
• Continue the stretch even after phonation has stopped 
Goal- No voice breaks  
 
Exercise 3: Contracting exercise- glide downward from highest to lowest note on the 
word “knoll” 
• Open pharynx, slow, no growl at the bottom, no muscling of the tone 
Goal- No voice breaks 
 
Exercise 4: Low impact adductory power exercise- sustain the musical notes C-D-E-F-G 
for as long as possible on the word “knoll” without the “kn” 
• Open pharynx, lip vibration 
Goal- sustained /o/ equal to vital capacity/ 80 mL/s 
 
Instructions 
• Produce all exercises as softly as possible with engaged voice (not breathy).  No 
hard glottal attacks at voice onset. 
• Tone placement should be forward with an open pharynx and constricted, 
vibrating lips (inverted megaphone shape). 
• Specific speech stimuli (knoll, oll) are selected to help achieve proper placement 
and pharyngeal opening. 
• The tone should not be muscled at the larynx; rely on interaction between 
abdominal contraction and breath support. 
• Practice consistency is encouraged; the participant charts progress on a record 
sheet.  Face videos are provided to guide practice sessions. 
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Appendix H: Withdrawal Questionnaire 
 
Please complete the questionnaire honestly.  You will not be subject to any penalty or 
repercussion as a result of withdrawal from this study.  We would like to know the reason 
for withdrawal as it may have implications for our results, data analysis, and continuation 
of the study. 
 
 
Please rate how difficult/ uncomfortable your stroboscopic examination (visualization of 
the vocal folds/ imaging of the larynx) was (circle one): 
 
No discomfort Mild discomfort Moderate discomfort   Extreme discomfort 
 
 
Please check all that apply: 
 
! I feel that I experienced fatigue, pain, soreness, or discomfort as a result of the 
exercise practices that I completed. 
 
! I felt discouraged by the required technique and was not able to achieve it 
independently. 
 
! I felt that the time commitment involved became too great to continue 
participation (if so, please indicate dose): 
o 2x1 
o 2x2 
o 2x4 
 
! Another personal matter prevented my full participation. 
 
! I do not wish to give a reason but will not continue my participation. 
 
! Other (please elaborate): 
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Appendix I: Average Weekly Phonation Times (s) 
 
 Check-In Week Number 
Su
bj
ec
t N
um
be
r 
 1 2 3 4 5 6 7 Mo. 
02 17 18 19 22 23 26 28 31 
07 25 27 27 26 25 30 34 25 
08 20 26 25 23 22 26 25 29 
12 13 11 15 15 14 13 18 14 
23 16 17 20 23 21 19 19 19 
24 21 21 19 20 21 21 20 20 
25A 18 19 21 18 22 28 28 24 
27A 16 18 18 20 20 22 19 17 
28 11 12 14 13 15 16 15 14 
29 15 26 24 32 32 32 32 24 
03 17 24 25 27 24 20 28 24 
05 21 22 24 24 24 21 23 19 
20 25 40 36 34 54 43 49 47 
13 19 27 32 35 33 28 31 26 
06 10 18 20 25 21 17 21 13 
30 20 20 26 25 27 34 32 30 
19 27 30 27 27 24 29 30 27 
15A 16 18 20 26 29 31 31 24 
21A 18 17 25 26 29 39 37 26 
14A 15 21 23 28 27 28 28 20 
22A 25 34 33 38 41 44 51 41 
01A 20 24 26 32 27 32 33 26 
17A 22 24 24 28 28 32 37 31 
09 21 49 39 34 35 35 27 25 
16 22 35 26 27 30 32 32 29 
18 21 20 27 33 39 58 60 40 
26 19 20 22 24 25 27 34 23 
10 11 15 15 15 18 16 14 16 
 
Low Dose 
Traditional Dose 
High Dose 
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